Document:

EX-10.7

 Exhibit 10.7 

CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 LICENSE AGREEMENT 

THIS LICENSE AGREEMENT (the “Agreement”) is dated as of June 17, 2015 (the “Signing Date”) by and
between Cytos Biotechnology Ltd. a Swiss company having a place of business at Wagistrasse 25, 8952 Schlieren, Switzerland (“Licensor”), and Checkmate Pharmaceuticals, LLC, having its registered office at 49 Trowbridge St. #3,
Cambridge, MA 02138, USA (“Checkmate”). Licensor and Checkmate may be referred to herein as a “Party” or, collectively, as “Parties”. 

RECITALS: 

WHEREAS, Licensor is engaged in the development of products based on its Qb VLP platform technology and owns certain
intellectual property and know-how covering Licensed Compounds and Licensed Products; 

WHEREAS, Checkmate is engaged in the research, development, and manufacturing of pharmaceutical products for the treatment of
cancer and is interested in researching, developing, manufacturing and commercializing Licensed Products for the treatment of cancer 

WHEREAS, Checkmate desires to license from Licensor and Licensor wishes to license to Checkmate, on an exclusive basis, the
right to research, develop, manufacture and commercialize Licensed Compounds and Licensed Products in the Field. 
 NOW,
THEREFORE, in consideration of the various promises and undertakings set forth herein, the Parties agree as follows: 

ARTICLE 1 
 DEFINITIONS

 Unless otherwise specifically provided herein, the following terms shall have the following meanings: 

1.1    “Accounting Standards” means, with respect to Checkmate, US GAAP (United States
Generally Accepted Accounting Principles) and, with respect to Licensor, the IFRS (International Financial Reporting Standards), in each case, as generally and consistently applied throughout the Party’s organization. Each Party shall promptly
notify the other in writing in the event that it changes the Accounting Standards pursuant to which its records are maintained, it being understood that each Party may only use internationally recognized accounting principles (e.g., IFRS,
US GAAP, etc.). 

 1.2    “Active Ingredient” means any substance
or mixture of substances intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or lo affect the structure and function of the body. 

1.3    “Adverse Event” means any serious “ untoward medical occurrence in a patient or
subject who is administered Licensed Product, but only if and to the extent that such serious untoward medical occurrence is required under Law s to be reported to applicable Regulatory Authorities. 

1.4    “Affiliate” means a Person that controls, is controlled by or is under common control with
a Party, but only for so long as such control exists. For the purposes of this Section 1.4, the word ‘‘control” (including, with correlative meaning, the terms “controlled by’” or “under the common control
with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person or entity, whether by the ownership of more than fifty percent (50%) of the voting stock of
such entity or by contract or otherwise. 
 1.5    “Bankruptcy Event” means, with respect to a
Party: (a) voluntary or involuntary proceedings by or against such Party that are instituted in bankruptcy under any insolvency law, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of
filing; (b) a receiver or custodian is appointed for such Party; (c) proceedings are instituted by or against such Party for corporate reorganization, dissolution, liquidation or winding-up of such
Party, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing; or (d) substantially all of the assets of such Party are seized or attached and not released within sixty
(60) days thereafter. 
 1.6    “Business Day” means a day other than Saturday or Sunday on
which banking institutions in New York, New York are open for business. 
 1.7    “Calendar
Quarter” means each three (3) month period commencing January 1, April 1, July 1 or October 1 of any year; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the
Effective Date to the end of the first full Calendar Quarter thereafter, and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement. 

1.8    “Calendar Year” means the period beginning on the 1st of January and ending on the 31st of December of the same year; provided, however, that (a) the first Calendar Year of the Term shall
commence on the Effective Date and end on December 31 of the same year and (b) the last Calendar Year of the Term shall commence on January 1 of the Calendar Year in which this Agreement terminates or expires and end on the date of
termination or expiration of this Agreement. 
 1.9    “Change of Control” means, with respect
to a Person: (a) a transaction or series of related transactions that results in the sale or other disposition of all or substantially all of such Person’s assets: or (b) a merger or consolidation in which such Person is not the
surviving corporation or in which, if such Person is the surviving corporation, the shareholders of such Person immediately prior to the consummation of such merger or consolidation do not, 

 
immediately after consummation of such merger or consolidation, possess, directly or indirectly through one or more intermediaries, a majority of the voting power of all of the surviving
entity’s outstanding stock and other securities and the power to elect a majority of the members of such Person’s board of directors; or (c) a transaction or series of related transactions (which may include a tender offer for such
Person’s stock or the issuance, sale or exchange of stock of such Person) if the shareholders of such Person immediately prior to the initial such transaction do not immediately after consummation of such transaction or any of such related
transactions, own, directly or indirectly through one or more intermediaries, stock or other securities of the entity that possess a majority of the voting power of all of such Person’s outstanding stock and other securities and the power to
elect a majority of the members of such Person’s board of directors. 
 1.10    “Checkmate Royalty
Term Patents” means, any Checkmate Patents relating to the manufacturing of Series I Products filed within [***] following the Signing Date. 

1.11    “Combination Product” means a product that includes a Licensed Compound and one or more
other Active Ingredient(s) (that are not Licensed Compounds) and the Licensed Compound and such Active Ingredient(s) are: (a) physically, chemically or otherwise combined or mixed with Licensed Compounds and produced as a single entity;
(b) packaged together in a single package or as a unit: or (c) packaged separately and according to their proposed labeling are for use only with each other, where both are required to achieve the intended use, indication, or effect. 

1.12    “Commercialization” or “Commercialize” means any and all activities
undertaken before and after Regulatory Approval of a Marketing Authorization Application for a Licensed Product and that relate to the marketing, promoting, distributing, importing or exporting for sale, offering for sale, and selling of Licensed
Compounds or Licensed Products, and interacting with Regulatory Authorities regarding any of the foregoing. 

1.13    “Commercially Reasonable Efforts” means: (a) with respect to the efforts to be
expended by a Party with respect to any objective, (including but not limited to those set forth in (b) below) such reasonable and good faith efforts as such Part) would normally use to accomplish a similar objective under similar
circumstances; and (b) with respect to any objective relating to Development or Commercialization of Licensed Compound or Licensed Product by a Party, the application by such Party, consistent with the exercise of its prudent scientific and
business judgment, of diligent efforts and resources to fulfill the obligation in issue, consistent with the level of efforts such Party would devote to a product at a similar stage in its product life as Licensed Compound or Licensed Product and
having profit potential and strategic value comparable to that of Licensed Compound or Licensed Product, taking into account, without limitation, commercial, legal and regulatory factors, target product profiles, product labeling, past performance,
the regulatory environment and competitive market conditions in the therapeutic area, safety and efficacy of the Licensed Compound or Licensed Product, the strength of its proprietary position and such other factors as such Party may reasonably
consider, all based on conditions then prevailing. 
 1.14    “Confidential Information” of a
Party, means information relating to the business, operations or products of a Party or any of its Affiliates, including any Know-How, not known or generally available to the public, that such Party discloses
to the other Party under this Agreement, or otherwise becomes known to the other Party by virtue of this Agreement. 

 1.15    “Controlled” means, with respect to
(a) Intellectual Property or (b) biological, chemical or physical material, that a Party or one of its Affiliates owns or has a license or sublicense to such Patent Rights, Know-How or material (or
in the case of material, has the right to physical possession of such material) and has the ability to grant a license or sublicense to, or assign its right, title and interest in and to, such Patent Rights,
Know-How or material a provided for in this Agreement without violating the terms of any agreement or other arrangement with any Third Party. 

1.16    “Copyrights” means (a) all copyrights and works of authorship, whether registered,
published or unpublished or unregistered throughout the world; (b) any registrations and applications therefor; (c) rights to databases of any kind under the Laws of any jurisdiction; (d) all extensions and renewals thereof; and
(e) any moral rights in or to the foregoing if available by Law of the applicable jurisdiction. 

1.17    “Cover”, “Covering” or “Covered” means, with respect to
Licensed Product, that the using, selling, or offering for sale of Licensed Product would, but for a license granted in this Agreement under the Licensor Patent Rights, infringe a Valid Claim of the Licensor Patent Rights in the country in which the
activity occurs. 
 1.18    “CYT003” means a Qb VLP as further described on Schedule
1.18. 
 1.19    “Delivery System” means a compound, device or mixture of compounds used to
formulate the Licensed Compound for the delivery to target sites of pharmacological actions or to improve the pharmacological action of the Licensed Compound. 

1.20    “Development” or “Develop” means, with respect to a Licensed Compound or
Licensed Product, the performance of all preclinical and clinical development (including efficacy, toxicology, pharmacology, test method development and stability testing, process development, formulation development, quality control development,
statistical analysis), clinical trials, manufacturing and regulatory activities that are required to obtain Regulatory Approval of such Licensed Compound or Licensed Product in the Territory. 

1.21    “Effective Date” means the date the following condition is met: closing of a financing
transaction (or a series of financing transactions) based on which Checkmate has received cash in the aggregate of [***]. If the Effective Date has not occurred within ninety (90) days following the Signing Date, this License Agreement shall be
considered void. 
 1.22    “EMA” means the European Medicines Agency or a successor agency
thereto. 
 1.23    “Encumbrance” means any pledge, charge, claim, encumbrance, security
interest, mortgage, easement, lien, right of first refusal or similar restriction, including any restriction on use, transfer, receipt of income or exercise of any other attribute of ownership (whether arising by contract or by operation of Law).

 1.24    “European Commission” means the
authority within the European Union that has the legal authority to grant Regulatory Approvals in the European Union based on input received from the EMA or other competent Regulatory Authorities. 

1.25    “Executive Officers” means, together, the Chief Executive Officer of Checkmate and the
Chief Executive Officer of Licensor. 
 1.26    “Existing Licenses” means the existing license
agreements between Licensor and [***], between Licensor and [***] between Licensor and [***]. 

1.27    “FDA” means the United States Food and Drug Administration or a successor federal agency
thereto. 
 1.28    “Field” means the diagnosis, treatment and/or prevention of cancer in humans
and animals. 
 1.29    “First Commercial Sale” means, on a country-by-country basis, the first commercial transfer or disposition for value of a Licensed Product in such country to a Third Party by Checkmate, or any of its Affiliates or Sublicensees after Regulatory
Approval for such Licensed Product has been obtained in such country. Sales prior to receipt of Regulatory Approval for such Licensed Product, such as so-called “treatment IND sales,” “named
patient sales” and “compassionate or emergency use sales” shall not be construed as a First Commercial Sale. 

1.30    “Fiscal Year” means Checkmate’s fiscal year as may be changed from time to time and
which is currently from January 1 to December 31. 
 1.31    “Generic Equivalent” means any
product with the same active ingredient and administration route as the Licensed Product that is (i) bioequivalent to and/or biosimilar to the Licensed Product and that is and sold under an approved MAA pursuant to 21 U.S.C. § 3550) or 42
U.S.C. § 262(k). or pursuant to the applicable law of the relevant jurisdiction or (ii) is sold under an ANDA or NDA pursuant to the FDA act. 

1.32    “Intellectual Property” means all rights in (a) Patent Rights, (b) trademarks
and service marks (whether registered or not), trademark and service mark applications and registrations, trade names, trade dress, logos, slogans, (c) Copyrights, (d) Know-How, and (e) technology,
software, trade secrets, rights in domain names and web pages, rights in designs, and other intellectual property rights, other than off-the-shelf computer programs, in
all cases whether or not registered or registrable and including registrations and applications for registrations of these and rights to apply for same and all rights and forms of protection of a similar nature or having equivalent or similar effect
to any of these anywhere in the world. 

1.33    “Know-How” means any: (a) scientific or
technical information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, that is not in the public domain or otherwise publicly known, including discoveries, inventions, trade secrets, devices, databases,
practices, protocols, regulatory filings, methods, processes (including manufacturing processes, specification and techniques), techniques, concepts, ideas, specifications, formulations, formulae, data (including pharmacological, biological,
chemical, toxicological, clinical and analytical information, quality control, trial and stability data), case report forms, medical records, 

 
data analyses, reports, studies and procedures, designs for experiments and tests and results of experimentation and testing (including results of research or development), summaries and
information contained in submissions to and information from ethical committees, or Regulatory Authorities, and manufacturing process and development information, results and data, whether or not patentable, all to the extent not claimed or
disclosed in a patent or patent application; and (b) compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material, including drug substance samples, intermediates of drug substance samples, drug
product samples and intermediates of drug product samples. “Know-How’’ includes any rights including copyright, database or design rights protecting such
Know-How. “Know-How” excludes Patent Rights. 

1.34    “Knowledge” means, with respect to a matter that is the subject of a given representation,
or warranty of Licensor, the knowledge, information or belief of any officer or director of Licensor, or such other employee of Licensor who would reasonably be expected to have knowledge of the matter in question, has, or should reasonably be
expected to have after making reasonable inquiry into the relevant subject matter. “Knowingly” means with Know ledge. 

1.35    “Law” or “Laws” means any and all applicable laws of any jurisdiction
which are applicable to any of the Parties or their respective Affiliates or (sub)licensees in carrying out activities hereunder or to which any of the Parties or their respective Affiliates or (sub)licensees in carrying out the activities hereunder
is subject, that may be in effect from time to time, and shall include all statutes, enactments, acts of legislature, laws, ordinances, rules, regulations, notifications, guidelines, directions, directives and orders of any statutory authority,
tribunal, board, or court or any central or state government or local authority or other governmental entity in such jurisdictions, including the International Conference on Harmonisation (ICH) guidance or other comparable regulation and guidance of
any applicable Regulatory Authority in the Territory, as applicable. 
 1.36    “Licensed
Compound” means any compound or biological product belonging to one of the three following series: 

(a)    Series 1: CYT003 (further described in Schedule 1.18) 

(b)    Series 2: a TLR9 Agonist, other than the G10 oligonucleotide contained in CYT003, packaged inside Qb
VLPs 
 (c)    Series 3: any TLR9 Agonist manufactured using the Licensor Technology (other than those in
Series 1 and 2). 
 1.37    “Licensed Compound Series” means any one of the series of Licensed
Compounds in Section 1.36—referred to individually in 1.36(a), (b) and (c). 

1.38    “Licensed Product” means any product, in any dosage form, formulation, presentation or
package configuration that is commercialized or undergoing research or preclinical or clinical development that contains or comprises one or more Licensed Compounds. 

1.39    “Licensor Copyrights” means all Copyrights that are Controlled by Licensor or any of its
Affiliates, as of the Effective Date or at any time’ thereafter during the Term and are necessary or useful in the research, Development, manufacture, use, or Commercialization of a Licensed Compound or Licensed Product. 

 1.40    “Licensor
Know-How” means all Know-How that is Controlled by Licensor or any of its Affiliates, as of the Effective Date or at any time thereafter during the Term, and is
necessary or useful in the research, Development, manufacture, use, or Commercialization of a Licensed Compound or Licensed Product. The Licensor Know-How shall include all
Know-How identified in the Technology and Program Transfer Plan. 

1.41    “Licensor Materials” means those certain materials identified in the Technology and
Program Transfer Plan as available for transfer from Licensor to Licensee (either for a fee or free of charge). 

1.42    “Licensor Patents” means all Patent Rights that are Controlled by Licensor or any of its
Affiliates, as of the Effective Date or at any time thereafter during the Term, and that are necessary or useful for the research, Development, manufacture, use, or Commercialization of a Licensed Compound or Licensed Product or that otherwise claim
or cover the Licensor Know-How (including, without limitation, Licensor’s interest in and to any Patents covering Joint Inventions). Listed on Schedule 1.42 are all Licensor Patents existing as of the
Effective Date. Licensor shall update Schedule 1.42 from time to time to include any new Patent Rights that come to be Controlled by Licensor or an) of its Affiliates al any time during the Term or after the Effective Date that are necessary or
useful for the research, Development, manufacture, use, or Commercialization of a Licensed Compound or Licensed Product or that otherwise claim or cover the Licensor Know -How. Licensor Patents expressly
exclude Patent Rights Controlled by an Affiliate of’ Licensor who becomes an Affiliate through a merger or acquisition by or of Licensor, which Patent Rights were Controlled by such Affiliate immediately prior to such merger or acquisition (any
such Patent Rights, collectively, the “Post-Transaction Licensor Patents”). 

1.43    “Licensor Technology” means the Licensor Copyrights, Licensor Patents, the Licensor Know-How and the Licensor Materials, and all other Intellectual Property rights Controlled by Licensor or any of its Affiliates at any time during the Term on or following the Effective Date that are necessary or
useful for the research, Development, manufacture, use, or Commercialization of a Licensed Compound or Licensed Product. 

1.44    “Loss of Market Exclusivity” means, with respect to any Licensed Product in any country,
the following has occurred: (a) the Net Sales of such Licensed Product in that country in any Calendar Year are less than 50% of the Net Sales in any Calendar Year of such Licensed Product in that country immediately preceding the launch of a
Generic Equivalent; and (b) the decline in such sales is attributable in material part to the marketing or sale in such country of a Generic Equivalent of such Licensed Product by a Third Party. 

1.45    “Marketing Authorization” means all approvals from the relevant Regulatory Authority
necessary to market and sell a Licensed Product in any country including pricing and pricing reimbursement approval. 

1.46    “Marketing Authorization Application” or “MAA” shall mean an application
or submission for Marketing Authorization of a pharmaceutical product filed with a Regulatory 

 
Authority to obtain marketing approval for such pharmaceutical product in a country or group of countries, including all additions, deletions or supplements thereto, and as any and all such
requirements may be amended, or supplanted, at any time. MAA as used herein shall include any New Drug Application (“NDA”) filed under 21 U.S.C. § 355 and any Biologics License Application (“BLA”) filed under
42 U.S.C. § 262. 
 1.47    “Net Sales” means the gross amounts received by Checkmate or
any of its Affiliates or Sublicensees for sales of Licensed Product to independent or unaffiliated Third Party purchasers of such Licensed Product after deductions (provided, however, that such deductions are calculated in accordance with GAAP,
consistently applied) for: 
 (a)    trade, cash and quantity discounts, credits, and refunds (including by
reason of rejection, return or recall of goods and rebates), other than early payment cash discounts; 

(b)    rebates, chargebacks and other similar allowances made, including with respect to sales paid for by any
governmental or regulatory authority, such as, by way of illustration and not limitation, Federal or state Medicaid, Medicare or similar state program or equivalent foreign governmental program; 

(c)    retroactive price reductions and early payment discounts that an-
actually allowed or granted: 
 (d)    that portion of administrative fees paid during the relevant period of
group purchasing organizations or pharmaceutical benefit managers relating to the Licensed Product; 

(e)    actual freight, postage, shipping and insurance expenses to the extent that such items are included in the
invoiced amount; 
 (f)    sales, import, export, excise, customs, and value added taxes, and duties imposed on
the sale of Licensed Products; 
 (g)    that portion of the annual fee on prescription drug manufacturers
imposed by the Patient Protection and Affordable Care Act, Pub. L. No. 111-148 (as amended) that Licensee or its Related Party, as applicable, allocates to the sales of Licensed Product in accordance with
Checkmate’s or its Affiliates’ or Sublicensees’ standard policies and procedures consistently applied across its products, as applicable; and 

(h)    invoiced amounts that are actually non-collectible and are written
off as non-collectible for the sale of Licensed Products. 
 For clarification, sale of Licensed
Product by Checkmate or any of its Affiliates to one another for resale to a Third Party shall not be deemed a sale for purposes of this definition of “Net Sales.” Further, transfers or dispositions of Licensed Product: (i) in
connection with patient assistance programs; (ii) for charitable or promotional purposes; (iii) for preclinical, clinical, regulatory or governmental purposes; or (iv) for use in any tests or studies reasonably necessary to comply
with any Law, regulation or request by a Regulatory Authority shall not, in each case of (i) through (iv), be deemed sales of such Licensed Product for purposes of this definition of “Net Sales.’’ 

 If a Licensed Product is sold as part of a Combination Product, the Net Sales of any such
Licensed Product shall be determined by multiplying the Net Sales (as defined in this Section 1.47) by the fraction A/(A+B), where A is the weighted (by sales volume) average sales price of the Licensed Product when sold separately in finished
form and B is the weighted (by sales volume) average sales price of the other product(s) or device(s) sold separately in finished form. In the event that such average sales price cannot be determined for both the Licensed Product and the other
product(s) in combination, Net Sales for the purpose of determining royalty payments shall be calculated using the formula where A is the reasonably estimated commercial value of the Licensed Product sold separately in finished form and B is the
reasonably estimated commercial value of the other product(s) or device(s) sold separately in finished form. 

1.48    “New Drug Application” means an application filed with the FDA under applicable Laws to
obtain Regulatory Approval in the United States for a new drug or biologic. 
 1.49    “Patent
Rights” means: (a) all national, regional and international patents and patent applications, including provisional patent applications, (b) all patent applications
continuations-in-part, provisionals, converted provisionals and continued prosecution applications, (c) any and all patents that have issued or in the future issue
from the foregoing patent applications ((a) and (b)), including utility models, petty patents and design and certificates of invention, and (d) any and all extensions or restorations by existing or future extension or restoration mechanisms,
including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications ((a), (b), and (c)). 

1.50    “Person” means any natural person, corporation, Unit, business trust, joint venture,
association, organization, company, partnership or other business entity, or any government or agency or political subdivision thereof 

1.51    “Phase I” means a human clinical trial of a Licensed Product, the principal purpose of
which is a preliminary determination of safety, tolerability, pharmacological activity or pharmacokinetics in healthy individuals or patients or similar clinical study prescribed by the Regulatory Authorities, including the trials referred to in 21
C.F.R. §312.2 l (a), as amended. 
 1.52    “Phase 2” means a human clinical trial of a
Licensed Product, the principal purpose of which is a determination of efficacy in the target patient population, which is prospectively designed to generate sufficient data that may permit commencement of pivotal clinical trials, or a similar
clinical study prescribed by the Regulatory Authorities, from time to time, pursuant to applicable Law or otherwise, including the trials referred to in 21 C.F.R. §312.2 l(b), as amended. 

1.53    “Phase 3” means a human clinical trial of a Licensed Product on a sufficient number of
subjects in an indicated patient population that is designed to establish that a or Licensed Product is safe and efficacious For its intended use and to determine the benefit/risk relationship, warnings, precautions, and adverse reactions that are
associated with such product in the dosage range to be prescribed, which trial is intended to support marketing approval of such Licensed Product, including all tests and studies that are required by the FDA from time to time, pursuant to applicable
Law or otherwise, including the trials referred to in 21 C.F.R. §312.21(c), as amended. 

 1.54    “Price Approvals” means, in those
countries in the Territory where Regulatory Authorities may approve or determine pricing and/or pricing reimbursement for pharmaceutical products, such pricing and/or pricing reimbursement approval or determination. 

1.55    “Qb VLP” means a Qbeta-derived virus like particle. 

1.56    “Regulatory Authority” means: (a) in the US, the FDA; (b) in the EU, the EMA or
the European Commission; or (c) in any other jurisdiction anywhere in the world, any regulatory body with similar regulatory authority over pharmaceutical or biotechnology products. 

1.57    “Regulatory Approval” means any and all approvals, licenses, registrations, or
authorizations of the relevant Regulatory Authority, including Price Approvals, necessary for the Development, manufacture, use, storage, import, transport or Commercialization of Licensed Product in a particular country or jurisdiction. For the
avoidance of doubt, Regulatory Approval to Commercialize Licensed Product shall include Price Approval. 

1.58    “Regulatory Documentation” means any and all applications, registrations, licenses,
authorizations and approvals (including all Regulatory Approvals), and non-clinical and clinical study authorization applications or notifications (including all supporting files, writings, data, studies and
reports) prepared for submission to a Regulatory Authority or research ethics committee with a view to the granting of any Regulatory Approval, and any correspondence to or with the EMEA or FDA or any other Regulatory Authority with respect to a
Licensed Compound, a Licensed Product (including minutes and official contact reports relating to any communications with any Regulatory Authority), and all data contained in any of the foregoing, including all regulatory authorizations, regulatory
drug lists, advertising and promotion documents, adverse event files and complaint files. 

1.59    “Royalty Term” means, on a Licensed Product by Licensed Product and country-by-country basis (and as further outlined under Section 5.3.2), the period from the First Commercial Sale of such Licensed Product in such country until the later
of (a) the last date on which such Licensed Product is Covered by a Valid Claim within the Licensor Patents or any Checkmate Royalty Term Patent in such country, (b) the date on which sale of such Licensed Product is no longer protected by
regulatory data exclusivity or market exclusivity in such country or (c) [***]. Royalties are payable only once with respect to the same unit of Licensed Product. 

1.60    “Senior Executive” means a member of senior management of a Party who is designated by
such Party to resolve disputes under this Agreement. 
 1.61    “Sublicensee” means a Person
other than an Affiliate of Checkmate to which Checkmate (or its Affiliate) has, pursuant to Section 2.2, granted sublicense rights under any of the license rights granted under Section 2.1. 

1.62    “Tax” or “Taxes” means any federal, state, local or foreign income, gross
receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property,
personal property, sales, use, transfer, registration, value added, alternative or add-on minimum, estimated, or other tax of any kind whatsoever, including any interest, penalty, or addition thereto, whether
disputed or not. 

 1.63    “Technology and Program Transfer Plan”
means the plan for the transfer of Licensor Know-How, Licensor Materials and Licensor’s CYT003 program, an outline of which is set forth on Schedule 1.63. 

1.64    “Territory” means all the countries in the world. 

1.65    “Third Party” means any Person other than Licensor, Checkmate or any of their respective
Affiliates. 
 1.66    “Third Party Action” means any Action made by a Third Party against
either Party that claims that a Licensed Compound or Licensed Product, or its use, Development, importation, manufacture or sale infringes or misappropriates such Third Party’s Intellectual Property rights. 

1.67    “Third Party License Agreement” means any agreement entered into by a Party or its
Affiliate with a Third Party, or any amendment or supplement thereto, in each case following the Effective Date. Whereby royalties, fees or other payments are to be made by a Party or its Affiliate lo such Third Party in connection with the grant of
rights under intellectual property rights Controlled by such Third Party, which rights are necessary or useful to research, Develop, manufacture, have made, import, export, use or Commercialize a Licensed Compound or Licensed Product. 

1.68    “TLR9 Agonist” means unmethylated CpG Oligodeoxynucleotide DNA or any other TLR agonist
that activates Toll-like receptor 9. 
 1.69    “United States” or “US” means
the United States of America, its territories and possessions. 
 1.70    “USD” means the lawful
currency of the United States. 
 1.71    “Valid Claim” means a claim (a) of an issued and
unexpired patent which has not lapsed or been revoked, abandoned or held unenforceable or invalid by a final decision of a court or governmental or supra-governmental agency of competent jurisdiction, unappealable or unappealed within the time
allowed for appeal, and which has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, reexamination or disclaimer or otherwise, or (b) of a patent application that is being diligently prosecuted and that has
not been pending for more than five (5) years from the earliest filing date from which such patent application is entitled to claim priority and which claim has not been revoked, cancelled, withdrawn, held invalid or abandoned. 

1.72    Other Terms. The definition of each of the following terms is set forth in the section of the
Agreement indicated below: 
  

			
	Defined Term	  	Section
	 “Action”
	  	6.5.2
	 “Agreement”
	  	Preamble
	 “Checkmate”
	  	Preamble
	 “Checkmate Indemnitees”
	  	9.2
	 “Checkmate Patent”
	  	6.4.2

			
	 “Controlling Party”
	  	6.6.3
	 “Development Support”
	  	3.2
	 “Effective Date”
	  	Preamble
	 “Joint Inventions”
	  	6.7
	 “Licensor”
	  	Preamble
	 “Licensor Indemnitees”
	  	9.1
	 “Manufacturing Support”
	  	3.4
	 “[***]”
	  	1.26
	 “Party” and
“Parties”
	  	Preamble
	 “Post-Transaction Licensor
Patents”
	  	1.42
	 “Regulatory Support”
	  	4.2
	 “Representatives”
	  	3.2
	 “Term”
	  	10.1

 ARTICLE 2 

LICENSES AND OTHER RIGHTS 

2.1    Grant of License to Checkmate. Subject to the terms and conditions of this Agreement, Licensor hereby
grants to Checkmate and its Affiliates, effective as of the Effective Date, an exclusive (even as to Licensor) worldwide right and license (with the right to sublicense, subject to the provisions of Section 2.2) under the Licensor Technology to
research, have researched, Develop, have developed, manufacture, have manufactured, import, have imported, export, have exported, distribute, have distributed, promote, have promoted, market, have marketed, sell, have sold, offer for sale, have
offered for sale and otherwise use and Commercialize Licensed Compounds and Licensed Products in the Territory in the Field. It is acknowledged and agreed by the Parties that, subject to the terms of this Agreement, the rights granted hereunder to
Checkmate and its Affiliates automatically include the right and license to use new, improved, modified or additional Licensor Technology which are Controlled by Licensor at any time during the Term. 

2.2    Right to Sublicense. Checkmate shall have the right, in its sole discretion, to grant sublicenses, in
whole or in part, through multiple tiers of Sublicensees, under the licenses granted in Section 2.1. Any sublicense agreement must be consistent with the terms and conditions of this Agreement. Checkmate is responsible for compliance of the
applicable sublicense agreement with the terms and conditions of this Agreement. In the event of any such sublicense, Checkmate shall continue to remain primarily liable for all liabilities and obligations under this Agreement, including the payment
obligations set forth in Section 5. Checkmate shall notify Licensor in writing of any sublicenses granted within thirty (30) days from granting such sublicense. 

2.3    Technology Transfer. After the Effective Date, Licensor shall make available to Checkmate the
Licensor Know-How and Licensor Materials and undertake the other activities set forth in the Technology and Program Transfer Plan in the manner and according to the schedule set forth therein. Checkmate shall
be responsible for certain costs as set forth in the Technology and Program Transfer Plan. The technology transfers set forth in the Technology and Program Transfer Plan shall occur in an orderly fashion and in a manner such that the value,
usefulness and confidentiality of the transferred Licensor Know-How, Licensor Materials and Regulatory 

 
Documentation are preserved in all material respects. In addition to implementing the Technology and Program Transfer Plan, during the Term, Licensor shall provide to Checkmate frill and prompt
disclosure, but in no event less frequently than semi-annually, of any Licensor Technology that becomes Controlled by Licensor or any of its Affiliates after the Effective Date and that is necessary or useful to Checkmate to conduct its activities
or exercise its rights as contemplated hereunder and shall, in the case of Licensor Know-How, promptly following such disclosure, transfer to Checkmate such Licensor
Know-How. 
 2.4    Exclusivity. Licensor agrees that during the
Term, neither it nor any of its Affiliates shall conduct or engage in any research, Commercialization or Development activities itself or sponsor or grant rights to any Third Party to conduct or engage in any other research, Commercialization or
Development activities on TLR9 Agonists in the Field without Checkmate’s prior written consent. The foregoing covenant shall expire upon a Change of Control of Licensor in the event that any Third Party which is a party lo a transaction giving
rise to a Change of Control would, based on its activities at the time of such transaction, cause the resulting entity to be in violation of the foregoing covenant (it being understood that the exclusivity of Checkmate’s license in
Section 2.1 and right to sublicense in Section 2.2 shall be unaffected by any such transaction). 

2.5    Covenant Not to Sue. Licensor hereby agrees that neither it nor any of its Affiliates shall enforce
against Checkmate, its Affiliates and Sublicensees any Post-Transaction Licensor Patents that Licensee may infringe in practicing the inventions claimed in the Licensor Patents. 

ARTICLE 3 
 DEVELOPMENT,
MANUFACTURE AND COMMERCIALIZATION OF PRODUCT 
 3.1    Development of Licensed Product by Checkmate.
After the Effective Date, Checkmate shall have the exclusive right and decision-making authority to research and Develop the Licensed Compounds and Licensed Products in the Field and to conduct (either itself or through its Affiliates, agents,
subcontractors and/or Sublicensees) all clinical trials and non-clinical studies Checkmate believes appropriate to obtain and maintain Regulatory Approval for Licensed Products in the Field. 

3.2    Licensor Support in Development. Commencing immediately after the Effective Date, Licensor shall
assist Checkmate with Development of the Licensed Compounds and Licensed Products by making its employees, consultants, contractors, advisors and agents (“Representatives”) that are knowledgeable regarding the Licensor Technology,
the Licensed Compounds or Licensed Products (including the properties and functions thereof), available lo Checkmate for scientific and technical explanations, advice and on-site support (collectively, the
“Development Support”). All Development Support requested by Checkmate shall be at Checkmate’s expense and at industry standard rates. 

3.3    Commercialization. Aller the Effective Date, Checkmate (or its Affiliates, Sublicensees or other
Third Parties designated by Checkmate) shall have the exclusive right and decision-making authority to Commercialize Licensed Products and Licensed Compounds in the Field. 

 3.4    Clinical and Commercial Manufacturing. After the
Effective Date, Checkmate (or its Affiliates, Sublicensees or other Third Parties designated by Checkmate) shall have the exclusive right to manufacture the Licensed Compounds and Licensed Products for use in the Field. After the Effective Date,
Licensor shall make Representatives that are knowledgeable regarding the Licensor Technology, the Licensed Compounds or Licensed Products available to Checkmate for scientific and technical explanations, advice and
on-site support, that may reasonably be required by Checkmate, relating to the manufacture of a Licensed Compound and Licensed Product (the “Manufacturing Support”), including manufacturing scale-up. All such Manufacturing Support shall be at Checkmate’s expense and at industry standard rates. 

3.5    Diligence by Checkmate. After the Effective Date, Checkmate shall use Commercially Reasonable Efforts
to Develop and Commercialize at least one Licensed Product in the Field. Checkmate shall have the exclusive right to determine, in its sole discretion, the development and launch strategy for a Licensed Product in the Field subject to its exercise
of Commercially Reasonable Efforts and the availability of any necessary Third Party licenses or other rights Activities by Checkmate’s Affiliates, Sublicensees, agents and subcontractors shall be considered as Checkmate’s activities under
this purposes or determining whether Checkmate has complied with its obligation to use Commercially Reasonably Efforts. 

3.6    Checkmate’s Right to Subcontract. Checkmate may exercise any of its rights, or perform any of
its obligations, under this Agreement (including any of the rights licensed in Section 2.1) by subcontracting the exercise or performance of all or any portion of such rights and obligations on Checkmate’s behalf. Any subcontract granted
or entered into by Checkmate as contemplated by this Section 3.6 of the exercise or performance of all or any portion of the rights or obligations that Checkmate may have under this Agreement shall not relieve Checkmate from any of its
obligations under this Agreement. 
 3.7    Trademarks. Alter the Effective Date, as between Licensor and
Checkmate, Checkmate shall have the sole authority to select trademarks for Licensed Products in the Field and shall own all such trademarks. 

3.8    Reporting. Checkmate shall, within sixty (60) days of each anniversary of the Effective Date,
provide Licensor with a written report summarizing in reasonable detail its major Development and, as applicable, Commercialization activities conducted since the last such report. All information and reports provided to Licensor pursuant to this
Section 3.8 shall be treated as Confidential Information of Checkmate hereunder. Notwithstanding the foregoing, Checkmate’s obligation to provide reports under this Section 3.8 shall expire: (i) with respect to Development, upon
receipt of Regulatory Approval for Licensed Product, and (ii) with respect to Commercialization, upon the third anniversary of the First Commercial Sale of Licensed Product hereunder. 

ARTICLE 4 
 REGULATORY
MATTERS 
 4.1    Regulatory Filings. After the Effective Date until the termination of this
Agreement, as between Checkmate and Licensor, Checkmate shall own and maintain all regulatory filings and Regulatory Approvals for Licensed Products in the Field, including all INDs and 

 
Marketing Authorization Applications. However, during such time as Checkmate is conducting development activities that reference Licensor’s existing IND (number BB- IND15217, filed as of 29 August 2012) and such IND remains open, then Licensor shall continue to maintain such IND with cooperation from Checkmate and other Third Party licensees of Licensed Product (such
cooperation to include, without limitation, the reporting of safety data as described in Section 4.3, and other activities as required by applicable Laws). Licensor shall maintain such IND through the renewal period expiring 31st of March 2016 at no additional cost to Checkmate. 

4.2    Communications with Regulatory Authorities. After the Effective Date, and subject to the terms of
Section 4.1 regarding the existing IND, Checkmate (or one of its Affiliates or Sublicensees) shall be responsible, and act as the sole point of contact, for communications with Regulatory Authorities in connection with the Development,
Commercialization, and manufacturing of Licensed Compounds and Licensed Products in the Field. After the Effective Date, subject to the terms of Section 4.1 regarding the existing IND, Licensor shall not initiate, with respect to any Licensed
Compound or Licensed Product in the Field, any meetings or contact with Regulatory Authorities without Checkmate’s prior written consent. After the Effective Date, to the extent Licensor receives any written or oral communication from any
Regulatory Authority relating to (a) a Licensed Compound or Licensed Product in the Field or (b) a Licensed Compound or product outside the Field which may impact Checkmate’s research and development plans or efforts or its regulatory
strategy. Licensor shall (i) refer such Regulatory Authority to Checkmate, and (ii) as soon as reasonably practicable (but in any event within twenty-four (24) hours), notify Checkmate and provide Checkmate with a copy of any written
communication received by Licensor or, if applicable, complete and accurate minutes of such oral communication. After the Effective Date, at the request of Checkmate, Licensor shall make available to Checkmate a Representative knowledgeable
regarding the Licensor Technology, the Licensed Compounds or Licensed Products, who shall, together with the representatives of Checkmate, participate in and contribute to meetings with the Regulatory Authorities with respect to regulatory matters
relating to the Licensor Technology (“Regulatory Support”). All such Regulatory Support shall be at Checkmate’s expense and at industry standard rates. 

4.3    Adverse Event Reporting. The Parties agree to comply with any and all Laws that are applicable as of
the Effective Date and thereafter during the Term in connection with Licensed Product safety data collection and reporting. After the Effective Date, if Licensor has or receives any information regarding any Adverse Event which may be related to the
use of Licensed Product, then Licensor shall provide Checkmate with all such information in English within such time that shall enable Checkmate to comply with all Laws and relevant regulations and requirements. Checkmate shall report to Licensor
any Adverse Event culminating in death or permanent disability of a patient or subject who is administered Licensed Product. 

4.4    Recalls. After the Effective Date, Checkmate shall have the sole right to determine whether and how
to implement a recall or other market withdrawal of a Licensed Product in the Field. 

 ARTICLE 5 

FINANCIAL PROVISIONS 

5.1    License Fee. Checkmate shall pay to Licensor a one-time, non-refundable license fee of $1 million USD, 50% of the license fee shall be due and payable within 30 days of the Effective Date, and the other 50% shall be due and payable within six months thereafter. In
the event of a Change of Control of Checkmate prior to the payment in full of the license fee, any amount of the license fee not already paid shall be immediately due and payable. 

5.2    Development Milestones. 

5.2.1    In partial consideration of the rights granted by Licensor to Checkmate and subject to the terms and
conditions set forth in this Agreement, Checkmate shall pay to Licensor a one-time, non-refundable milestone payment within thirty (30) days alter the achievement
of each of the following milestones for the first Licensed Compound in a Licensed Compound Series developed and commercialized in the Field. 

[***] 

5.2.2    Each milestone payment in this Section 5.2 shall be payable only upon the first achievement of such
milestone for the first Licensed Product from the same Licensed Compound Series and no amounts shall be due for subsequent or repeated achievements of such milestone in with Licensed Products from such Licensed Compound Series. For purposes of
clarity each milestone payment in this Section 5.2 shall be payable only one time irrespective of the number of indications pursued for such Licensed Product in each Licensed Compound Series. 

5.2.3    If the first Licensed Product in a Licensed Compound Series is abandoned for any reason prior to the First
Commercial Sale and an additional Licensed Product in the same Licensed Compound Series is advanced into clinical development, Checkmate shall resume milestone payments starting at the event subsequent to the last milestone payment that was made
with respect to the first Licensed Product in such Licensed Compound Series. 
 5.2.4    If a development
milestone event has been skipped with a Licensed Product in a Licensed Compound Series, and a subsequent development milestone event is achieved with respect to such Licensed Product in such Licensed Compound Series, then the milestone payment for
the preceding milestone event shall become due and payable upon the achievement of such subsequent milestone event. For example, in the event that a New Drug Application is filed for a Licensed Product in Series 2 based on data from a Phase 2
clinical trial, the milestone payment for the dosing of the first patient in a Phase 3 clinical trial shall be payable together with the milestone payment clue for the filing of the New Drug Application for such Series 2 Licensed Product. 

5.2.5    Reductions for Third Party Milestone Payments. If Checkmate or any of its Affiliates enter into one
or more Third Party License Agreements that are required or which Checkmate or any of its Affiliates reasonably believe are necessary to avoid or settle an alleged infringement of such Third Party’s Intellectual Property rights arising from the
use, Development, manufacture or sale of a Licensed Compound, Checkmate shall be entitled to deduct from any amount payable to Licensor under Section 5.2 [***] of any amounts paid by Checkmate or such Affiliates pursuant to such Third Party
License Agreement(s) in respect of the Licensed Product (or Licensed Compound) which gave rise to the payment obligation under Section 5.2; provided, that in no event shall the foregoing deduction reduce the amount due to Licensor pursuant to
Section 5.2 by more than [***]. 

 5.2.6    Change of Control Transaction Milestone. Provided
that Checkmate has at least one Licensed Product in Development in either Licensed Compound Series 1 or Licensed Compound Series 2, in the event of a Change of Control of Checkmate during the Term, Checkmate will pay Licensor a one-time, non-refundable transaction milestone equal to the lesser of: [***] of the total valuation placed on Checkmate in such Change of Control transaction(s). The
transaction milestone shall be due within 30 days of the closing of the Change of Control transaction (or series of related transactions), may be paid in cash or such freely tradable securities (as the case may be) and shall be creditable against
certain development milestones set forth in Section 5.2, as follows: (a) [***] of the transaction milestone is creditable against the development milestones for ‘‘New Drug Application filing with the FDA for regulatory approval in the
United States” and (b) [***] of the transaction milestone is creditable against the development milestones for “first MAA filing for regulatory approval in the European Union.” By way of example, if Checkmate had previously made a
transaction milestone payment of [***] million and subsequently triggered the milestone payment for an NDA filing in the U.S. with a product from Licensed Compound Series 2, then the base milestone payment of [***] million would be reduced by [***],
resulting in a development milestone payment of $[***]. Exempt from this Section 5.2.6 shall be a Change of Control resulting from the sale of shares in one or more venture financing rounds, or a Change of Control resulting from a merger for
stock of two private companies. Any further Change or Control of the merged private company will be deemed a Change of Control under this Section 5.2.6. 

5.3    Royalty Payments for Licensed Product. 

5.3.1    Royalty Rate. As further consideration for the rights granted to Checkmate hereunder, during each
applicable Royalty Term, Checkmate shall pay to Licensor a royalty on Net Sales of each Licensed Product in the Territory during each Calendar Year at the following rates: 

[***] 
 For clarity, the
calculation of aggregate Net Sales in the leftmost column of the preceding table shall include all Licensed Products, irrespective of the series to which such products belong. Royalties are payable only once with respect to the same unit of Licensed
Product. 
 5.3.2    Royalty-Exclusions and Step-Down. 

(a)    If, throughout the Term of this Agreement, there is no Valid Claim of a Licensor Patent Covering a
particular Licensed Product in a particular country, then no royalties shall be due for the sale of such Licensed Product in such country. 

(b)    If, during the Royalty Term, there is no Valid Claim of a Licensor Patent covering a Licensed Product in a
particular country, then, for such country, the royalties payable to Licensor for Net Sales of such Licensed Product in such country shall be reduced by [***] of the applicable royalty rate(s) set forth in Section 5.3.1. For purposes of
clarity, no royalties shall be due for Licensed Products not Covered by either a Licensor Patent or Licensor Know-How. 

 5.3.3    Reductions for Third Party License Agreements. If
Checkmate or any of its Affiliates enter into a Third Party License Agreement(s) required to avoid or settle an alleged infringement of such Third Party’ Intellectual Property rights arising from the use, deduct from any amount payable to
Licensor under Section 5.3.1 [***] of any amounts paid by Checkmate or such Affiliates pursuant to such Third Party License Agreement(s) in respect of the Licensed Product which gave rise to the payment obligation under Section 5.3.1;
provided, that in no event shall the foregoing deduction reduce the amount due to Licensor pursuant to Section 5.3.1 for any Calendar Quarter by more than [***]. 

5.3.4    Royalties for Additional Licensed Products. The royalty rate applicable to subsequent Licensed
Products in a Licensed Compound Series, after the first Licensed Product in a Licensed Compound Series, shall be reduced as follows: 

(a)    For Licensed Products in Licensed Compound Series 2, by [***]; and 

(b)    For Licensed Products in Licensed Compound Series 3, by [***]. 

As examples: (i) for the second Licensed Product in Licensed Compound Series 2, the royalty rate for Net Sales of less than [***], and (ii) for the
third Licensed Product in Licensed Compound Series 2, [***]. 
 5.3.5    Loss of Market Exclusivity. In
the event of a Loss of Market Exclusivity for any Licensed Product in any country, provided that Checkmate has taken and is taking all Commercially Reasonable Efforts available to it to enforce any Patent Rights it may own or control that could
prevent relevant sales of a Generic Equivalent in such country, then the royalty rates applicable to Net Sales of such Licensed Product in such country in accordance with Section 5.3 shall be reduced by [***]. Such reduction shall be first
applied with respect to such country starting with sales in the Calendar Quarter following the Calendar Quarter in which Loss of Market Exclusivity occurs for such Licensed Product in such country. In no event shall the royalty deductions under
Section 5.3.2 and this Section 5.3.5 be cumulative. 
 5.3.6    Timing of Payment. Royalties
payable under this Section 5.3 shall be payable on Net Sales and shall accrue at the time the payment for the sale of Licensed Product is received. Royalty obligations that have accrued during a particular Calendar Quarter shall be paid, on a
Calendar Quarter basis, within ninety (90) days after the end of each Calendar Quarter during which the royalty obligation accrued. 

5.3.7    Royalty Reports and Records Retention. Within ninety (90) days after the end of each Calendar
Quarter during which Licensed Product has been sold, Checkmate shall deliver to Licensor, together with the applicable royalty payment due for such Calendar Quarter, a written report, on a Licensed Product-by-Licensed Product and a country-by-country basis, of Net Sales subject to royalty payments for such Calendar Quarter.
Such report shall be deemed “Confidential Information” of Checkmate subject to the obligations of ARTICLE 7 of this Agreement. For one year after each sale of Licensed Product occurs, Checkmate shall, and shall ensure that its Affiliates
and Sublicensees, keep complete and accurate records of such sale in sufficient detail to confirm the accuracy of the royalty calculations hereunder. 

 5.4    Mode of Payment and Currency. All payments to
Licensor hereunder shall be made by deposit of USD in the requisite amount to such bank account as Licensor may from time to time designate by written notice to Checkmate. With respect to sales not denominated in USD, Checkmate shall convert
applicable sales in foreign currency into USD by using the then current and reasonable standard exchange rate methodology applied to its external reporting or other standard practice used for the preparation or its audited financial statements.
Based on the resulting sales in USD, the then applicable royalties shall be calculated. The Parties may vary the method of payment set forth herein at any time upon mutual written agreement, and any change shall be consistent with the local Law at
the place of payment or remittance. 
 5.5    Legal Restrictions. If at any time legal restrictions
prevent the remittance by Checkmate of all or any part or royalties due on Net Sales in any country, Checkmate shall have the right and option to make such payment either by depositing the amount thereof in local currency to an account in the name
of Licensor in a bank or other depository selected by Licensor in such country. 
 5.6    Audits. 

5.6.1    Audits Generally. During the Royalty Term and for one Calendar Year thereafter, and not more than
once in each Calendar Year, Checkmate shall permit, and shall cause its Affiliates to permit, an independent certified public accounting firm or nationally recognized standing selected by Licensor, and reasonably acceptable to Checkmate, to have
access to and to review, during normal business hours upon reasonable prior written notice, the applicable records of Checkmate and its Affiliates to verify the accuracy of the royalty reports and payments under this ARTICLE 5. Such review may cover
the records for sales made in any Calendar Year ending not more than one year prior to the date of such request. The accounting firm shall disclose to Licensor and Checkmate only whether the royalty reports are correct or incorrect and the specific
details concerning any discrepancies. No other information shall be provided to Licensor. 

5.6.2    Audit-Based Reconciliation. If such accounting firm conclude that additional amounts were owed
during such period, then Checkmate shall pay the additional amounts within thirty (30) days after the date Licensor delivers to Checkmate such accounting firm’s written report. If such accounting firm concludes that an overpayment was
made, such overpayment shall be fully creditable against amounts payable in subsequent payment periods or, at Checkmate’s request, shall be promptly reimbursed to Checkmate. Licensor shall pay for the cost of any audit, unless Checkmate has
underpaid Licensor by at least ten percent (10%), in which case Checkmate shall pay for the cost of the audit. 

5.6.3    Audit Confidentiality. Each Party shall treat all information that it receives under this
Section 5.6 in accordance with the confidentiality provisions of ARTICLE 7 of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with the other Party obligating such firm to retain all such
financial information in confidence pursuant to such confidentiality agreement, except to the extent necessary for such Party to enforce its rights under this Agreement. 

 5.7    Withholding Tax. Licensor shall be responsible for
the payment of any and all faxes levied on account of the royalties and other payments paid to Licensor by Checkmate or its Affiliates or Sublicensees under this Agreement. If Law requires that Taxes be deducted and withheld from royalties or other
payments paid under this Agreement Checkmate shall (i) deduct those Taxes and interests and penalties assessed thereon from the payment or from any other payment owed by Checkmate hereunder; (ii) pay the Taxes to the proper governmental
body; (iii) send evidence of the obligation together with proof of Tax payment to Licensor within one hundred (100) days following such payment; (iv) remit the net amount, after deductions or withholding made under this
Section 5.7; and (v) cooperate with Licensor in any way reasonably requested by Licensor, to obtain available reductions, credits or refunds of such Taxes; provided, however, that Licensor shall reimburse Checkmate for Checkmate’s
reasonable and documented out-of-pocket expenses incurred in providing such assistance. 

ARTICLE 6 
 INVENTIONS
AND PATENTS 
 6.1    Patent Listing under Public Health Services Act. Each Party shall immediately
give written notice to the other Party of any certification of which they become aware filed pursuant to 42 USC. §262(l)(3) (or any amendment or successor statute thereto) claiming that any Licensor Patents covering Licensed Compound or
Licensed Product, or the manufacture or use of each of the foregoing, are invalid or unenforceable, or that infringement shall not arise from the manufacture, use or sale of a product by a Third Party. 

6.2    Listing of Patents. For any approved MAA filed as an NDA under 2 U.S.C. § 355, Checkmate shall
have the sole right to determine which of the Licensor Patents, if any, shall be listed for inclusion in the FDA’s Approved Drug Licensed Products with Therapeutic Equivalence Evaluations (commonly referred to as the Orange Book), or any
successor Law in the United States, together with any comparable Laws in any country. To the extent the FDA ever requires a similar patent listing for approved biological products, Checkmate shall have the same right with respect to any approved MAA
filed as a BLA under 42 U.S.C. § 262. 
 6.3    Further Assurances. Licensor shall require all
of its employees, and use its best efforts to require its contractors and agents, and any Affiliates and Third Parties working on its behalf under this Agreement (and their respective employees, contractors and agents), to assign to Licensor any
Licensor Technology. 
 6.4    Patent Prosecution and Maintenance. 

6.4.1    Licensor Patents. 

(a)    The Parties acknowledge that the patents and patent applications set forth on Schedule 1.42 are the subject
of the Existing Licenses. For so long as such Existing Licenses are in effect, such patents and patent applications are subject to certain priority and consent rights related to prosecution, enforcement and abandonment as provided in the Existing
Licenses. 
 (b)    Checkmate shall bear [***] of the costs and expenses incurred after the Effective Date of
filing, prosecuting and maintaining Licensor Patents which have claims which are necessary or useful for the research, Development, manufacture, use or Commercialization of 

 
a Licensed Product; provided that, if Licensor grants or has granted rights to any Licensor Patents which are necessary or useful for the research, Development, manufacture, use or
Commercialization of a Licensed Compound to Third Parties in addition to [***] and to Checkmate under any Licensor Patents in fields other than the Field, each such Third Party shall share equally [***] Checkmate in such costs and expenses incurred
after the Effective Date. 
 (c)    If Licensor receives notice from [***], pursuant to the relevant Existing
Licenses, that [***] has elected not to file or to continue to prosecute or maintain a Licensor Patent in any country, then Licensor shall notify Checkmate in writing promptly following its receipt of such notice. In such case, Checkmate shall have
the right to pursue the filing or support the continued prosecution or maintenance of such Licensor Patent in Licensor’s name using a mutually agreeable patent attorney or law firm. Licensor shall provide to Checkmate reasonable assistance in
prosecuting Licensor Patents to the extent possible, including providing such data in Licensor’s Control that is, in Checkmates reasonable judgment, needed to support the prosecution of a Licensor Patent. If Checkmate elects to continue such
prosecution or maintenance, then Checkmate shall bear the costs and expenses of filing, prosecuting and maintaining the applicable Licensor Patents incurred after such election; provided that, if Licensor grants rights to any Third Parties under any
Licensor Patents in fields other than the Field, each such Third Party shall share equally with Checkmate in such costs and expenses. 

(d)    If Licensor has the right to review and provide comments or suggestions to [***] or any other Third Party
Licensees of Licensed Products regarding the prosecution or maintenance of Licensor Patents in any country. Licensor agrees to provide Checkmate with the opportunity to provide its comments and suggestions to Licensor and Licensor agrees to use its
best efforts to provide Checkmate’s comments and suggestions to [***] or any other Third Party Licensees of Licensed Products. 

6.4.2    Checkmate Patents. Checkmate shall own any Know-How
developed by Checkmate or any of its Affiliates or a Third Party on behalf of Checkmate and shall have the right, but not the obligation, to file, prosecute and maintain Patent Rights covering or claiming any such Know-How (“Checkmate Patent”). Checkmate shall bear all costs and expenses of filing, prosecuting and maintaining Checkmate Patents and Licensor shall have no particular rights with respect thereto.

 6.5    Enforcement of Patents and Know-How. 

6.5.1    Notice. 

(a)    The Parties acknowledge that the patents and patent applications set forth on Schedule 1.42 are the subject
of the Existing Licenses. For so long as such Existing Licenses are in effect, such patents and patent applications are subject to certain priority and consent rights related to prosecution, enforcement and abandonment as provided in the Existing
Licenses. If Licensor has the right to review and provide comments or suggestions to [***] or any other Third Party Licensees of Licensed Products regarding the enforcement of Licensor Patents in any country, Licensor agrees to provide Checkmate
with the opportunity to provide its comments and suggestions to Licensor and Licensor agrees to provide Checkmate’s comments and suggestions to [***] or any other Third Party Licensees of Licensed Products. 

 (b)    If either Party knows or believes that an infringement,
unauthorized use, misappropriation, ownership claim, threatened infringement or other similar activity by a Third Party exists or has occurred with respect to any Licensor Technology, or if a Third Party claims that any Licensor Patent is invalid or
unenforceable, the Party possessing such knowledge or belief shall notify the other Part) and provide it with all details that are known by such Party. 

(c)    In the event that Licensor believes that a Checkmate Patent, if any, is being infringed by a Third Party or
if a Third Party claims that any Checkmate Patent is invalid or unenforceable, Licensor shall notify Checkmate and provide it with details of such infringement or claim. 

6.5.2    Right to Bring an Action. Checkmate shall have the exclusive right to attempt to resolve any
infringement or claim, including by filing an infringement suit, defending against such claim or taking other similar action, with respect to the use or practice of a Licensor Patent in the Field (each, an “Action”) and to
compromise or settle any such infringement or claim: provided, however, that in case such infringement also involves any product comprising lgE coupled to Qb VLPs or CYT003, then Checkmate’s right shall be subject to the permission of [***]
that Checkmate may initiate or participate in legal actions against such infringement, which permission Licensor shall use commercially reasonable efforts to obtain. At Checkmate’s request, Licensor shall immediately provide Checkmate with all
relevant documentation (as may be requested by Checkmate) evidencing that Checkmate is validly empowered by Licensor to take such an Action. Licensor is obligated to join Checkmate in such Action if Checkmate determines that it is necessary to
demonstrate “standing to sue.’’ If Checkmate does not intend to prosecute or defend an Action, Checkmate shall promptly inform Licensor, in which case Licensor shall be entitled to assume the prosecution or defense of such Action at
its own cost. 
 6.5.3    Costs of an Action. Subject to the respective indemnity obligations of the
Parties set forth in ARTICLE 9, the Party taking an Action under Section 6.5.2 shall pay all costs associated with such Action, other than (subject to Section 6.5.5) the expenses of the other Party if the other Party elects to join such
Action (as provided in the last sentence of this paragraph). Each Party shall have the right to join an Action relating to a Licensor Patent, at its own expense 

6.5.4    Settlement. Neither Party shall settle or otherwise compromise any Action by admitting that any
Licensor Patent is invalid or unenforceable without the other Party’s prior written consent and, in the case of Licensor, Licensor may not settle or otherwise compromise an Action in a way that adversely affects or would be reasonably expected
to adversely affect Checkmate’s rights or benefits hereunder without Checkmate’s prior written consent. 

6.5.5    Reasonable Assistance. The Party not enforcing or defending Licensor Patents shall provide
reasonable assistance to the other Party, including providing access to relevant documents and other evidence and making its employees available, subject to the other Party’s reimbursement, on an on-going
basis, of any reasonable out-of-pocket expenses incurred by the non-enforcing or
non-defending Party in providing such assistance. 

6.5.6    Distribution of Amounts Recovered. Any amounts recovered by the Party taking an Action pursuant to
this Section 6.5, whether by settlement or judgment, shall be allocated in the following order: (i) to reimburse the Party taking such Action for any costs incurred; (ii) to 

 
reimburse the Party not taking such Action for its costs incurred in such Action, if it joins such Action: and (iii) the remaining amount of such recover) shall be allocated to Checkmate and
deemed to be Net Sales for the Calendar Quarter in which the amount is paid and Checkmate shall pay to Licensor a royalty on such remaining amount based on the royalty rates set forth in Section 5.3. 

6.5.7    Checkmate Patents. Checkmate shall have the sole right and authority, but not the obligation, to
enforce Checkmate Patents against any Third Party infringer: provided that Licensor shall provide reasonable assistance to Checkmate with respect thereto, including providing access to relevant documents and other evidence and making its employees
available, subject to Checkmate’s reimbursement, on an on-going basis, of any out-of-pocket expenses incurred in providing
such assistance. 
 6.6    Third Party Actions Claiming Infringement. 

6.6.1    Notice. If a Party becomes aware of any Third Party Action, such Party shall promptly notify the
other Party of all details regarding such claim or action that is reasonably available to such Party. 

6.6.2    Right to Defend. Checkmate shall have the right, at its sole expense, but not the obligation, to
defend a Third Party Action and to compromise or settle such Third Party Action. If Checkmate declines or fails to assert its intention to defend such Third Party Action within sixty (60) days after sending (in the event that Licensor is the
notifying Party) or receipt (in the event that Checkmate is the notifying Party) of notice under Section 6.6.1 then Licensor shall have the right to defend such Third Party Action. The Party defending such Third Party Action shall have the sole
and exclusive right to select counsel for such Third Party Action. 
 6.6.3    Consultation. The Party
defending a Third Party Action pursuant to Section 6.6.2 shall be the “Controlling Party.” The Controlling Party shall consult with the non-Controlling Party on all material aspects of
the defense. The non-Controlling Party shall have a reasonable opportunity for meaningful participation in decision-making and formulation of defense strategy. The Parties shall reasonably cooperate with each
other in all such actions or proceedings. The non-Controlling Party shall be entitled to be represented by independent counsel of its own choice at its own expense. 

6.6.4    Appeal. In the event that a judgment in a Third Party Action is entered against the Controlling
Party and an appeal is available, the Controlling Party shall have the first right, but not the obligation, to file such appeal. In the event the Controlling Party docs not desire to file such an appeal, it shall promptly, in a reasonable time
period (i.e., with sufficient time for the non-Controlling Party to take whatever action may be necessary) prior to the date on which such right to appeal shall lapse or otherwise diminish, permit the non-Controlling Party to pursue such appeal at such non-Controlling Party’s own cost and expense. If Law requires the other Party’s involvement in an appeal, the
other Party shall be a nominal party of the appeal and shall provide reasonable cooperation to such Party at such Party’s expense 

6.6.5    Costs of an Action. Subject to the respective indemnity obligations of’ the Parties set forth
in ARTICLE 9, the Controlling Party shall pay all costs associated with such Third Party 

 
Action other than the expenses of the other Party if the other Party elects to join such Third Party Action (as provided in the last sentence of this paragraph). Each Party shall have the right
to join a Third Party Action defended by the other Party, at its own expense. 
 6.6.6    No Settlement
Without Consent. Neither Party shall settle or otherwise compromise any Third Party Action by admitting that any Licensor Patent is invalid or unenforceable without the other Party’s prior written consent and, in the case of Licensor.
Licensor may not settle or otherwise compromise a Third Party Action in a way adversely affects or would be reasonably expected to adversely affect Checkmate’s rights and benefits hereunder without Checkmate’s prior written consent. 

6.7    Joint Intellectual Property Ownership and Disclosure. All rights, title and interest in any
inventions which are discovered or invented jointly by the Parties (as determined by inventorship under the U.S. patent laws) (“Joint Inventions”) shall be jointly owned by the Parties. Each Party shall promptly disclose all Joint
Inventions to the other Party. Checkmate shall have the first right, but not the obligation, to assume responsibility for the preparation, filing, prosecution and maintenance of all US, EU and foreign patent applications in the Field using patent
counsel reasonably acceptable to both Parties. As mutually agreed by the Parties, one Party shall have the first right, but not the obligation, to assume responsibility for the preparation, filing, prosecution and maintenance of all US, EU and
foreign patent applications outside the Field using patent counsel reasonably acceptable to both Parties. Both Parties shall participate in and cooperate in such preparation, filing, prosecution and maintenance. In the event that one Party fails to
exercise its right to assume such responsibility with respect to a patentable Joint Invention, then the other Party shall have the right, but not the obligation, to assume such responsibility. The Parties shall share equally the expenses for the
preparation, filing, prosecution and maintenance of Joint Inventions. 
 6.8    Commercial Exploitation of
Joint Inventions. Each party, as a joint owner of the Joint Inventions shall have the right, without additional compensation to the other, to make, have made, import, have imported, use or have used, sell or have sold, and develop or have
developed the Joint Inventions outside the Field. During the term and of this Agreement, Checkmate shall have the exclusive right to make, have made, import, have imported, use or have used, sell or have sold, and develop or have developed the Joint
Inventions in the Field subject to the other terms of this Agreement. Nothing in this Section 6.8 shall be construed as a grant to the other Party of any intellectual property rights owned or Controlled by the other Party other than those
granted in this Agreement. 
 ARTICLE 7 

CONFIDENTIALITY 

7.1    Confidentiality Obligations. Each Party agrees that, for the Term and for five (5) years
thereafter, each Party shall, and shall ensure that its Representatives hold in confidence all Confidential Information disclosed to it by the other Party pursuant to this Agreement, unless, as established by its written records, such information:

 7.1.1    is or becomes generally available to the public other than as a result of disclosure by the
recipient; 

 7.1.2    is already known by or in the possession of the
recipient at the time of disclosure by the disclosing Party; 
 7.1.3    is independently developed by recipient
without use of or reference to the disclosing Party’s Confidential Information; or 
 7.1.4    is obtained
by recipient from a Third Part) that has not breached obligations of confidentiality. 
 7.2    Permitted
Disclosures. The recipient shall not disclose any or the Confidential Information, except to Representatives of the recipient who need to know the Confidential Information for the purpose of performing the recipient’s obligations, or
exercise its rights, under this Agreement and who are bound by obligations of non-use and non-disclosure substantially similar to those set forth herein. The recipient
shall be responsible for any disclosure or use of the Confidential Information by such Representatives. The recipient shall protect Confidential Information using not less than the same care with which it treats its own confidential information, but
at all times shall use at least reasonable care. Each Party shall: (a) implement and maintain appropriate security measures to prevent unauthorized access to, or disclosure of, the other Party’s Confidential Information; (b) promptly
notify the other Party of any unauthorized access or disclosure of such other Party’s Confidential Information; and (c) cooperate with such other Party in the investigation and remediation of any such unauthorized access or disclosure.

 7.3    Permitted Use. 

7.3.1    Notwithstanding Section 7.1, Checkmate may use Licensor’s Confidential Information for the
purpose of performing its obligations, or exercising its rights, under this Agreement, including for purposes of: 

7.3.2    filing or prosecuting patent applications, subject to the terms of Section 6.3; 

7.3.3    prosecuting or defending litigation; 

7.3.4    conducting pre-clinical studies or clinical trials pursuant to
this Agreement: 
 7.3.5    seeking or maintaining Regulatory Approval of Licensed Products; or 

7.3.6    complying with Law, including securities Law and the rules of any securities exchange or market on which
Checkmate’s securities may be listed or traded. 
 7.3.7    In addition to the foregoing, Checkmate may, in
connection with the Development or Commercialization of Licensed Compounds and/or Licensed Products under this Agreement and in discussions with its Board of Directors, Scientific Advisory Board, existing investors and potential investors, and
potential partners or acquirors disclose Confidential Information of Licensor to any Third Party, provided that such Third Party is bound by obligations of confidentiality at least as stringent as the ones herein. 

7.3.8    In connection with any permitted filing by either Party of this Agreement with any governmental body, the
filing Party shall endeavor to obtain confidential treatment of economic, 

 
trade secret information and such other information as may be requested by the other Party, and shall provide the other Party with the proposed confidential treatment request with reasonable time
for such other Party to provide comments, and shall include in such confidential treatment request all reasonable comments of the other Party. 

7.4    Required Disclosure. The recipient may disclose the Confidential Information lo the extent required
by Law or court order: provided, however, that the recipient promptly provides to the disclosing party prior written notice of such disclosure and provides reasonable assistance in obtaining an order or other remedy protecting the Confidential
Information from public disclosure. 
 7.5    Publications. Licensor shall not publish any information
relating to a Licensed Compound or Licensed Product in the Field without the prior written consent of Checkmate (which consent may be withheld or given in Checkmate’s sole discretion), unless such information has already been publicly disclosed
either prior to the Effective Date or after the Effective Date through no fault of Licensor or otherwise not in violation of this Agreement. Checkmate shall have the right to make such publications as it chooses, in its sole discretion, without the
approval of Licensor. Licensor shall submit to Checkmate for Checkmate’s written approval (which approval be granted or denied in Checkmate’s sole discretion) any publication or presentation (including in any seminars, symposia or
otherwise) of information related directly or indirectly to a Licensed Product for review and approval at least ninety (90) days prior to submission for the proposed date of publication or presentation. 

7.6    Publicity. 

7.6.1    Publicity and Use of Names. In the event a Party desires to make a public disclosure announcing the
transaction contemplated by this Agreement, such Party shall submit the proposed disclosure in writing to the other Party at least five Business Days prior to the date of disclosure to provide an opportunity to comment thereon. Only upon the
approval of the other Party (such approval not to be unreasonably withheld or delayed) may such public disclosure be made. The Parties shall mutually agree on the timing and content of a joint press release regarding the execution and relevant
details of this Agreement. Neither Party shall use the name of the other Party in any publicity, advertising or announcements or for any other commercial purpose without the prior written approval of the Party whose name is to be used. In connection
with the execution of this Agreement, the Parties anticipate issuing a joint press release in a form which shall be mutually agreed upon in writing by the Parties. 

7.6.2    Required Disclosure. In the event that either Party believes it is required to issue a press
release or make another public announcement relating to this Agreement to comply with Law it may issue such press release or announcement if (a) the other Party agrees: or (b) it is required to make such disclosure to comply with Law and
provides the text of such planned disclosure to the other Party no less than five (5) days prior to disclosure, or such shorter period as may be required in order to issue such press release or announcement within the time frame required by Law
and to consider in good faith any requested changes by the other Party. 

 ARTICLE 8 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

8.1    Representations and Warranties. Each Party represents and warrants to the other Party that, as of the
Effective Date and as of the Effective Date: 
 8.1.1    such Party is duly organized and validly existing under
the Laws of the jurisdiction of its incorporation or organization: 
 8.1.2    such Party has taken all action
necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement: 

8.1.3    this Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable
against such Party in accordance with the terms of this Agreement except as enforcement may be limited by applicable bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’
rights generally and by general equitable principles. The execution, delivery and performance of this Agreement by such Party docs not conflict with, breach or create in any Third Party the right to accelerate, terminate or modify any agreement or
instrument to which such Party is a party or by which such Party is bound, and does not violate any Law of any governmental body having authority over such Party; and 

8.1.4    such Party has all right, power and authority to enter into this Agreement, to perform its obligations
under this Agreement. 
 8.2    Additional Representations and Warranties of Licensor. Licensor represents
and warrants to Checkmate that, as of the Effective Date: 
 8.2.1    no consent by any Third Party or
governmental authority is required with respect to the execution and delivery of this Agreement by Licensor or the consummation by Licensor of the transactions contemplated hereby; 

8.2.2    to Licensor’s actual knowledge, without having conducted any further inquiry or investigation, there
are no limits or conditions in Licensor’s agreements for the Licensed Product or Licensor Technology with any Third Party which may have a material adverse effect on Checkmate’s use of Licensor Technology pursuant to the licenses granted
in this Agreement or on Checkmate’s diligent and complete fulfillment of its obligations under this Agreement: 

8.2.3    no claims have been asserted, or, to Licensor’s Knowledge, threatened by any Person,
(a) challenging the validity, effectiveness, or ownership of Licensor Technology, and/or (b) to the effect that the use, reproduction, modification, manufacturing, distribution, licensing, sublicensing, sale or any other exercise of rights
in any of Licensor Technology infringes or shall infringe on any Intellectual Property right of any Person; 

8.2.4    to the Knowledge of Licensor, the Licensor Patents are not the subject of any litigation procedure,
discovery process, interference, reissue, reexamination, opposition, appeal proceedings or any other legal dispute; 

8.2.5    to the Knowledge of Licensor, no Third Party has filed, pursued or maintained or threatened in writing to
file, pursue or maintain any claim, lawsuit, charge, complaint or other action alleging that any Licensor Patent is invalid or unenforceable; 

 8.2.6    all issuance, renewal, maintenance and other material
payments that are or have become finally due with respect to the Licensor Technology have been timely paid by or on behalf of Licensor; 

8.2.7    all Licensor Patents have been properly filed, prosecuted and maintained; 

8.2.8    it has the fell right to provide the Licensor Materials to Checkmate and to transfer to Checkmate all
right, title and interest in and to the Licensor Material to be provided to Checkmate pursuant to this Agreement; 

8.2.9    To the Know ledge of Licensor, each of the patents and patent applications included among the Licensor
Patents that is owned (in w hole nr in part) by the Licensor properly identifies each and every inventor of the inventions claimed therein and does not identify any person as an inventor who is not correctly identified as an inventor, as determined
in accordance with applicable Laws. Each inventor named on the patents and patent applications included among the Licensor Patents that are owned (in whole’ or in part) by the Licensor has executed an assignment of his or her entire right,
title, and interest in and to such patent or patent application, and in and to each and ever) invention described, embodied, or claimed therein, to the Licensor. To the Knowledge of Licensor, no such inventor has any contractual or other obligation
that would preclude or otherwise interfere with any such assignment or otherwise conflict with the obligations of such inventor to the Licensor under such agreement with the Licensor. 

8.2.10    subject to the terms of the Existing Licenses, Licensor has all right, title and interest in and to the
Licensor Technology and Licensor Technology is free and clear of any liens, charges, security interests, mortgage, encumbrances or rights of others to possession or use that would preclude Checkmate’s use of the Licensor Technology pursuant to
the licenses granted in this Agreement or which would impede of preclude the diligent and complete fulfillment of its obligations under this Agreement: 

8.2.11    except as set forth in the Existing Licenses, Licensor has not previously licensed, assigned,
transferred, or otherwise conveyed any right, title or interest in and to the Licensor Technology to any Third Party, including any rights with respect to Licensed Compound or Licensed Product, that would preclude Checkmate’s use of Licensor
Technology pursuant to the licenses granted in this Agreement; 
 8.2.12    there are no (a) Actions
relating to the Licensor Technology, the Licensed Compound or the Licensed Products pending or, to the Knowledge of Licensor, threatened against Licensor or any of its Affiliates; and (b) there are no Actions pending or, to the Knowledge of
Licensor, threatened, that question the legality or propriety of the transactions contemplated by this Agreement or the consummation of the transactions contemplated herein or therein or which would reasonably be expected to prevent, hinder or delay
the consummation of any of the transactions contemplated by this Agreement; and 
 8.2.13    to Licensor’s
actual knowledge, without having conducted any further inquiry or investigation, and except as cited during prosecution of the Licensor Patents or as intended to be cited upon commencement of substantive prosecution, there are no patents, patent
applications, patent publications, articles or other prior art references, public use or disclosure, sales or offers to 

 
sell, prior invention, other prior art, or any other material information, that could adversely affect the validity or enforceability of, or is otherwise pertinent to, any patent or patent
application included among the Licensor Patents. The Licensor (to the extent the Licensor is or was an applicant in respect of any patent or patent application included within the Licensor Patents) and, to Licensor’s actual knowledge, without
having conducted any further inquiry or investigation, each inventor of the inventions claimed in the patents and patent applications included in the Licensor Patents has complied in all material respects with all applicable duties of candor and
good faith in dealing with the U.S. Patent and Trademark Office and any foreign patent offices, including, without limitation, the duty to disclose to any such patent office all information known to be material to the patentability of each such
invention. 
 8.3    Disclaimer of Warranties. EXCEPT FOR THE EXPRESS WARRANTIES SET FORT 1 IN THIS
ARTICLE 8, LICENSOR MAKES NO REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND LICENSOR SPECIFICALLY DISCLAIMS ANY OTHER REPRESENTATIONS AND WARRANTIES, WHETHER WRITTEN
OR ORAL, EXPRESS, STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT
OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 ARTICLE 9 

INDEMNIFICATION AND INSURANCE 

9.1    Indemnification by Checkmate. Checkmate shall indemnify, defend and hold Licensor and its Affiliates
and each of their respective employees, officers, directors and agents (the “Licensor Indemnitees”) harmless from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys’ fees) to the
extent arising out of Third Party claims or suits related to: (a) Checkmate’s negligence or willful misconduct; (b) breach by Checkmate of its representations or warranties set forth in this Agreement; or (c) the development of a
Licensed Compound or Licensed Product by or on behalf of Checkmate following the Effective Date; provided, however, that Checkmate’s obligations pursuant to this Section 9.1 shall not apply (i) to the extent such claims or suits
result from the negligence or willful misconduct of any of the Licensor Indemnitees, or (ii) with respect to claims or suits arising out of breach by Licensor of its representations, warranties or covenants set forth in this Agreement. 

9.2    Indemnification by Licensor. Licensor shall indemnify, defend and hold Checkmate and its Affiliates
and each of their respective agents, employees, officers and directors (the “Checkmate Indemnitees”) harmless from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys’ fees) to the
extent arising out of Third Party claims or suits (including Third Party Actions) related to: (a) Licensor’s negligence or willful misconduct; (b) breach by Licensor of its representations, warranties or covenants set forth in this
Agreement; or (c) the development of a Licensed Compound or Licensed Product prior to the Effective Date: provided, however, that Licensor’s obligations pursuant to this Section 9.2 shall not apply (i) to the extent that such
claims or suits result from the negligence or willful misconduct of’ an) of the Checkmate Indemnitees or (ii) with respect to claims or suits arising out of a breach by Checkmate of its representations or warranties set forth in ARTICLE 8.

 9.3    No Consequential Damages. EXCEPT WITH RESPECT TO
EACH PARTY’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 9.1 OR SECTION 9.2 AS APPLICABLE, IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, INCIDENTAL,
CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOSS OF PROFITS, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREIN OR ANY BREACH HEREOF.
NOTWITHSTANDING THE FOREGOING NOTHING IN THIS AGREEMENT SHALL LIMIT EITHER PARTY FROM SEEKING OR OBTAINING ANY REMEDY AVAILABLE UNDER LAW FOR ANY BREACH OF BY THE OTHER PARTY OF ITS CONFIDENTIALITY AND NON-USE
OBLIGATIONS UNDER ARTICLE 7. 
 9.4    Notification of Claims; Conditions to Indemnification Obligations.
As a condition to a Party’s right to receive indemnification under this ARTICLE 9, it shall: (a) promptly notify the other Party as soon as it becomes aware of a claim or suit for which indemnification may be sought pursuant hereto;
(b) cooperate, and cause the individual indemnitees to cooperate, with the indemnifying Party in the defense, settlement or compromise of such claim or suit; and (c) permit the indemnifying Party to control the defense, settlement or
compromise of such claim or suit, including the right to select defense counsel. In no event, however, may the indemnifying Party compromise or settle an) claim or suit in a manner which admits fault or negligence on the part of the indemnified
Party or any indemnitee without the prior written consent of the indemnified Party. Each Party shall reasonably cooperate with the other Party and its counsel in the course of the defense of any such suit, claim or demand, such cooperation to
include using reasonable efforts to provide or make available documents, information and witnesses. The indemnifying Party shall have no liability under this ARTICLE 9 with respect to claims or suits settled or compromised without its prior written
consent. 
 9.5    Insurance. During the Term, each Party shall obtain and maintain, at its sole cost and
expense, insurance (including any self-insured arrangements) in types and amounts that are reasonable and customary in the pharmaceutical and biotechnology industry for companies of comparable size, at a comparable stage of development and engaged
in comparable activities in the countries in which such Party operates. It is understood and agreed that this insurance shall not be construed to limit either Party’s liability with respect to its indemnification obligations hereunder. Each
Party shall, except to the extent self-insured, provide to the other Party upon request a certificate evidencing the insurance such Party is required to obtain and keep in force under this Section 9.5. 

ARTICLE 10 
 TERM AND
TERMINATION 
 10.1    Term and Expiration. The term of this Agreement (the “Term”)
shall commence on the Effective Date and, unless earlier terminated as provided in this ARTICLE 10, shall continue in full force and effect, on a country-by-country and
Licensed Product-by-Licensed Product basis until the date on which the Royalty Term in such country with respect to such Licensed Product expires, at which time this Agreement shall expire in its entirety with
respect to such Licensed Product in such country and the terms of Section 10.7 shall apply. 

 10.2    Termination of the Agreement for Convenience. At
any time during the Term, Checkmate may, at its convenience, terminate this Agreement in its entirety, or on a Licensed Product-by-Licensed Product, upon ninety
(90) days’ prior written notice to Licensor. 
 10.3    Termination upon Material Breach or
Bankruptcy. 
 10.3.1    Material Breach. If a Party breaches any of its material obligations under
shall be entitled to terminate this Agreement, the Party not in default may give to the breaching Party a written notice specifying the nature of the default, requiring it to cure such breach, and stating its intention to terminate this Agreement if
such breach is not cured within sixty (60) days. If such breach is not cured within sixty (60) days after the receipt of such notice the Party not in default shall be entitled to terminate this Agreement immediately by written notice to
the other Party. For clarity, such material obligations may apply to the performance of either: (a) this Agreement in its entirety, in which case this provision shall apply to the entire Agreement; or (b) a specific Licensed Product or
Licensed Product(s), in which case this provision shall apply only to such affected Licensed Product or Licensed Product(s). 

(a)    In the event of a material breach by Licensor of either (i) the grant of exclusivity in ARTICLE 2, (ii)
the confidentiality provisions in ARTICLE 7 or (iii) the representations and warranties in Sections 8.1.3 and 8.1.4 that is either undisputed or confirmed by the dispute resolution procedure described in Section 10.3.2, then in lieu of
terminating this Agreement, Licensee may, by written notice to Licensor, (1) convert all licenses granted to Checkmate under Section 2.1 and all sublicenses granted by Checkmate pursuant to Section 2.2 of this Agreement to worldwide,
irrevocable, sub-licensable exclusive licenses in the Field, (2) terminate the provisions in Sections 3.5, 3.8, 6.7 and 7.6 of this Agreement, (3) reduce the royalties payable to Licensor for Net
Sales of any Licensed Product in any country by fifty percent (50%) of the applicable royalty rate(s) set forth in Section 5.3.1, and (4) seek injunctive relief. The Parties agree that that any breach listed in this Section 10.3.1(a)
will cause Licensee substantial and irreparable damages and, therefore, in the event of any such breach, in addition to other remedies set forth in this Section 10.3.1(a), Licensee shall have the right to seek specific performance and other
injunctive and equitable relief (without being required to post a bond or other security). If Licensee elects the special remedy described in this Section 10.3.1(a), then such remedy shall be Licensee’s sole and exclusive remedy for such
material breach by Licensor. 
 10.3.2    Material Breach Dispute. Any dispute regarding an alleged
material breach of this Agreement shall be resolved in accordance with ARTICLE 11 hereof. 

10.3.3    Termination Upon Bankruptcy Event. If, during the Term, a Party undergoes a Bankruptcy Event,
then, subject to applicable Laws and the terms of this Agreement, the other Party may terminate this Agreement in its entirety upon thirty (30) days’ prior written notice to the bankrupt Party. 

10.4    Effects of Termination. 

10.4.1    General Effects. Upon any termination of this Agreement with respect to a Licensed Product, the
following terms and conditions shall apply with respect to such Licensed Product(s) and country(ies) as are the subject of such termination: 

 (a)    All licenses granted to Checkmate under Section 2.1
shall terminate. 
 (b)    Checkmate shall return to Licensor or, at Licensor’s option, destroy, at
Licensor’s cost and expense, all relevant records and materials in its possession or control containing or comprising the Licensor Know-How and the Licensor Materials, or such other Confidential
Information of Licensor, to the extent solely related to such Licensed Product(s) and country(ies): provided, however, that Checkmate shall have the right to retain one copy of such Licensor Know-How and one
sample of Licensor Materials and such other Confidential In formation of Licensor. 
 (c)    Checkmate shall at
Licensor’s request (i) sell such materials (in whole or in part) to Licensor at a price equal to Checkmate’s costs of goods, plus a twenty- five percent (25%) mark-up (transportation and
transfer costs shall be at Licensor’s cost and expense), or (ii) destroy any and all chemical, biological or physical materials relating to or comprising such Licensed Product(s), including clinical supplies of such Licensed Product(s),
that are Controlled by Checkmate, or (iii) sell such materials to a Third Party. 
 (d)    Checkmate and its
Affiliates and Sublicensees shall be entitled, during the eighteen (18) month period following such termination, to sell any commercial inventory of such Licensed Product(s) which remains on hand as of the date of the termination, so long as
Checkmate pays to Licensor the royalties applicable to said subsequent sales in accordance with the terms and conditions set forth in this Agreement. Any commercial inventory remaining following eighteen (18) month period shall be offered for
sale to Licensor at a price equal to [***]. 
 (e)    Each of Checkmate’s Sublicensees shall continue to
have the rights and licenses set forth in its sublicense agreements, which agreements shall be automatically assigned to Licensor (to the extent authorized therein); provided, however, that such Sublicensee is not then in breach of any of its
material obligations under its sublicense agreement. 
 10.4.2    Additional Effects Upon Termination For
Licensed Products in Licensed Compound Series 1. For clarity, none of the provisions in this Section 10.4.2 shall apply to a limited termination by Checkmate pursuant to Section 10.3.1(a). 

(a)    Immediately following a notification of termination pursuant to Sections 10.2 or 10.3, the Parties
shall agree upon a transition plan for the transition to Licensor of development and commercial activities then being conducted by Checkmate and materials to the extent solely related to such Licensed Product(s) and country(ies) and the wind-down of
such activities by Checkmate. Checkmate shall, upon written request by Licensor, (I) transfer to Licensor at Licensor’s cost and expense, all Regulatory Documentation and Regulatory Approvals prepared or obtained by or on behalf of
Checkmate prior to the date of such termination, to the extent solely related to such Licensed Product(s) and country(ies) and transferable, and Checkmate shall have the right to retain one copy of such transferred documentation and Regulatory
Approvals for record-keeping purposes, and (2) to the extent not prohibited by Law, wind down any ongoing clinical trials with respect to such Licensed Product(s), or at Licensor’s option, transfer such clinical trials to Licensor at
Licensor’s cost and expense. Licensor shall have the option, at its discretion, to purchase from Checkmate the relevant clinical trial supplies of Licensed Product at [***]. 

 (b)    If either Party terminates this Agreement prior to the
initiation by Checkmate of a Phase 1 Trial of a Licensed Product, no reversion royalties shall be owed to Checkmate pursuant to this Section. If Checkmate terminates this Agreement after the initiation by Checkmate of a Phase 1 Trial of Licensed
Product but prior to the completion of such trial, then Licensor shall pay Checkmate a post-termination [***] on Net Sales of such Licensed Product, up to a maximum aggregate payment equal to three times Checkmate’s total Development Expenses
(as defined below) incurred in connection with the Development of the terminated Licensed Product. If Checkmate terminates this Agreement alter the completion by Checkmate of a Phase 1 Trial of a Licensed Product and before completion of a Phase 3
Trial of such Licensed Product, then Licensor shall pay Checkmate a [***] on Net Sales of such Licensed Product, up to a maximum aggregate payment equal to three times Checkmate’s total Development Expenses (as defined below) incurred in
connection with the Development of the terminated Licensed Product. If Checkmate terminates this Agreement after the completion by Checkmate of a Phase 3 Trial of a Licensed Product and before the filing of a New Drug Application or MAA for such
Licensed Product, then Licensor shall pay Checkmate a [***] on Net Sales of such Licensed Product, up to a maximum aggregate payment equal to three times Checkmate’s total Development Expenses (as defined below) incurred in connection with the
Development of the terminated Licensed Product. If Checkmate terminates this Agreement after the filing of a New Drug Application or MAA for a Licensed Product, then Licensor shall pay Checkmate a [***] on Net Sales of such Licensed Product.
Licensor’s payment of royalties pursuant to this Section shall be calculated in accordance with the terms of Section 5.3, applied mutatis mutandis to Licensor, excluding the royalty reductions, credits and step-downs described
therein. 
 (c)    As used herein, “Development Expenses” means (i) any expenses accrued prior to
or after the Effective Date, and which expenses are specifically attributable to the Development of Licensed Products, (ii) any costs (whether internal or costs paid by a Party to a Third Party contract manufacturer) incurred after the
Effective Date for any of the following with respect to bulk API or finished Licensed Product: manufacturing process development and validation, process improvements, associated analytical development and validation and the manufacture and testing
of clinical and stability, confirmation or consistency lots (including registration stability, process development, qualification, process validation, QA, and test batches), and (iii) any expenses incurred in connection with the preparation,
submission and maintenance of any Regulatory- Documentation, and (iv) any royalty, milestone, or other payments payable to Third Parties on account of the Development of Licensed Products. Any costs for Checkmate’s internal FTEs shall be
calculated at a fixed rate to be agreed by the Parties in connection with the negotiation of the transition plan described in Section 10.4.2(a). 

10.5    Rights on Bankruptcy or Insolvency. All rights and licenses granted under or pursuant to this
License Agreement by Licensor are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses to intellectual property as defined under Section 101 of the Bankruptcy Code. Licensor agrees that
Checkmate shall retain and may fully exercise its rights and elections under the Bankruptcy Code. If a case is commenced during the term of this License Agreement by or against a Party under the Bankruptcy Code then, unless and until this Agreement
is rejected as provided in the Bankruptcy Code, such Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee) shall
perform all of the obligations provided in this License Agreement to be performed by such Party. If a case is commenced during the term of this License Agreement by or against a Party under the 

 
Bankruptcy Code, this License Agreement is rejected or not assumed as provided in the Bankruptcy Code and the other Party elects to retain its rights hereunder as provided in the Bankruptcy Code,
then the Party subject to such case under the Bankruptcy Code (in any capacity, including debtor-in- possession) and its successors and assigns (including a Title 11
trustee), shall provide to the other Party copies of all information necessary for such other Party to prosecute, maintain and enjoy its rights under the terms of this License Agreement promptly upon such other Party’s written request therefor.
All rights, powers and remedies of the non-bankrupt Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in
equity (including, without limitation, the Bankruptcy Code) in the event of the commencement of a case by or against a Party under the Bankruptcy Code. Section 365(n) and the terms of this Section 10.5 shall apply and shall be enforced in
and by every court, tribunal, arbitrator, regulatory body or official resolving disputes between the Parties with respect to rights in intellectual property, whether such court, tribunal, arbitrator, regulatory body or official is located in the
U.S. or in any other nation or jurisdiction. 
 10.6    Survival. 

10.6.1    Notwithstanding the expiration or termination of this Agreement pursuant to Sections 10.2 or 10.3, the
following provisions shall survive: ARTICLE 7, ARTICLE 9, ARTICLE 11 and ARTICLE 13; and Sections 8.3, 10.4, 10.6, 10.7, 10.8 and any other provision that, by its terms or implication, is required to survive in order to give effect to any of
the’ foregoing. 
 10.6.2    Expiration or termination of this Agreement shall not relieve the Parties of
any liability that accrued hereunder prior to the effective date of such termination. In addition, termination of this Agreement shall not preclude either Party from pursuing all rights and remedies it may have hereunder or at Law or in equity with
respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. 

10.7    Effects of Expiration. As of the effective date of expiration of the Royalty Term with respect to a
given Licensed Product and country, the license from Licensor to Checkmate and its Affiliates under Section 2.1 and all sublicenses granted by Checkmate to its Sublicensees under Section 2.2, shall convert to a fully paid, worldwide,
royalty free, irrevocable, perpetual, exclusive, and sublicensable license under the Licensor Technology to research, develop, manufacture, have manufactured, use and Commercialize Licensed Compound and such Licensed Product in the Field in such
country. 
 10.8    Other Remedies. Termination of this Agreement for any reason shall not release either
Party from any liability or obligation that already has accrued prior to such termination. Termination of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect or limit,
any rights or remedies that otherwise may be available at Law or in equity. 

 ARTICLE 11 

DISPUTE RESOLUTION 

11.1    Disputes. The Parties recognize that disputes as to certain matters may from time to time arise
during the Term which relate to either Party’s rights and/or obligations hereunder. It is the objective of the Parties to establish under this ARTICLE 11 procedures to facilitate the resolution of disputes arising under this Agreement in an
expedient manner by mutual cooperation and without resort to litigation. In the event that the Parties are unable to resolve such dispute through diligent review and deliberation by the Senior Executives within thirty (30) days from the day
that one’ Party had designated the issue as a dispute in written notice to the other Party, then either Party shall have the right to escalate such matter to the Executive Officers as set forth in Section 11.2. 

11.2    Escalation to Executive Officers. Either Party may, by written notice to the other Party, request
that a dispute that remains unresolved by the Senior Executives for a period of thirty (30) days as set forth in Section 11.1 arising between the Parties in connection with this Agreement, or a dispute relating to material breach, be
resolved by the Executive Officers, within fifteen (15) days alter referral of such dispute to them If the Executive Officers cannot resolve such dispute within fifteen (15) days alter referral of such dispute to them, then, at any time
alter such fifteen (15) day period, either Party may proceed to enforce any and all of its rights with respect to such dispute. 

11.3    Litigation; Venue. The Parties agree that, except as otherwise set forth in Section 11.1 or
11.2, any dispute, controversy or claim arising out of, related to or in connection with Agreement shall be finally determined by litigation in the federal courts located in the Stale of New York, or to a state court in such jurisdiction if
applicable Law precludes federal court jurisdiction. 
 ARTICLE 12 

ACTIVITIES BETWEEN SIGNING AND EFFECTIVE DATE 

12.1    Provision of Materials Prior to Effective Date. Licensor shall provide Checkmate, at
Checkmate’s expense, with certain Licensor Materials prior to the Effective Date, including CYT003 and Qbeta specific monoclonal antibodies, as may be reasonably requested by Checkmate for the purpose of enabling Checkmate’s conduct of
certain non- clinical research activities using such Licensor Materials. 

12.2    Return Upon Delayed Effectiveness. If the Effective Date has not occurred ninety (90) days
following the Signing Date, then, upon Licensor’s written request, Checkmate shall return to Licensor or, at Checkmate’s option, destroy, at Licensor’s cost and expense, all Licensor Materials provided to Checkmate as described in
Section 12.1 and shall assign to Licensor any Intellectual Property rights generated by or on behalf of Checkmate through the use or testing of such Licensor Materials. 

ARTICLE 13 

MISCELLANEOUS PROVISIONS 

13.1    Relationship of the Parties. Nothing in this Agreement is intended or shall be deemed, for
financial, tax, legal or other purposes, to constitute a partnership, agency, joint venture or employer-employee relationship between the Parties. 

 13.2    Assignment. 

13.2.1    Limitation. Subject to the provisions of this Section 13.2, neither this Agreement nor any of
the rights and obligations of a Party under this Agreement shall be assigned to any person or entity, without the prior written consent of the other Party. Notwithstanding the foregoing, a Party may, without the consent of the other Party, assign
this Agreement or its rights or obligations under this Agreement: (i) to an Affiliate; (ii) in connection with the transfer or sale of all or substantially all of its assets to which this Agreement relates; or (iii) in the event of a
Change of Control. 
 13.2.2    Continuing Obligations. This Agreement shall be binding upon, and inure to
the benefit of each Party, its Affiliates, and its permitted successors and assignee. Each Party shall be responsible for the compliance by its Affiliates with the terms and conditions of this Agreement, and for clarity, in the event of an
assignment to an Affiliate, the assignor party shall remain as principal obligor for all or any obligations and liabilities assigned to such Affiliate under the terms of this Agreement. 

13.2.3    Void Assignments. Any purported assignment not in accordance with this Section 13.2 shall be void.

 13.3    Performance and Exercise by Affiliates. Checkmate shall have the right to have any of
its obligations hereunder performed, or its rights hereunder exercised, by, any of its Affiliates and the performance of such obligations by any such Affiliate(s) shall be deemed to be performance by Checkmate: provided, however, that Checkmate
shall be responsible for ensuring the performance of its obligations under this Agreement and that any failure of any Affiliate performing obligations of Checkmate hereunder shall be deemed to be a failure by Checkmate to perform such obligations.
For clarity, the foregoing means that Checkmate may designate an Affiliate to perform its obligations hereunder or to be the recipient of Licensor’s performance obligations hereunder. 

13.4    Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments and
to do all such other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

13.5    Accounting Procedures. Each Party shall calculate all amounts, and perform other accounting
procedures required, under this Agreement and applicable to it in accordance with GAAP. 
 13.6    Force
Majeure. Neither Party shall be liable to the other Party or be deemed to have breached or defaulted under this Agreement for failure or delay in the performance of any of its obligations under this Agreement for the time and to the extent such
failure or delay is caused by or results from acts of God, earthquake, riot, civil commotion, terrorism, war, strikes or other labor disputes, fire, flood, failure or delay of transportation, omissions or delays in acting by a governmental
authority, acts of a government or an agency thereof or judicial orders or decrees or restrictions or any other reason which is beyond the control of the respective Party. The Party affected by force majeure shall provide the other Party with fill
particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and shall use Commercially Reasonable Efforts to overcome the difficulties created
thereby and to resume performance of its obligations hereunder as soon as practicable. 

 13.7    No Trademark Rights. No right, express or implied,
is granted by this Agreement to a Party to use in any manner the name or any other trade name or trademark of the other Party in connection with the performance of this Agreement or otherwise. 

13.8    Entire Agreement of the Parties; Amendments. This Agreement and the Schedules hereto constitute and
contain the entire understanding and agreement of the Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties, whether oral or written,
regarding such subject matter. No waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party. 

13.9    Captions. The captions to this Agreement are for convenience only, and are to be of no force or
effect in construing or interpreting any of the provisions of this Agreement. 
 13.10    Governing Law.
This Agreement shall be governed by and interpreted in accordance with the laws of the State of New York, excluding application of any conflict of laws principles that would require application of the Law of a jurisdiction outside of the State of
New York. 
 13.11    Notices and Deliveries. Any notice, request, approval or consent required or
permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by facsimile (receipt verified) or by express courier service (signature required) to the Party to
which it is directed at its address or facsimile number shown below or such other address or facsimile number as such Part) shall have last given by notice to the other Party. 

 

			
	 If to Checkmate, addressed to:

	
	 Checkmate Pharmaceuticals LLC

	 49 Trowbridge St. #3

	 Cambridge, MA 02138, USA

	 Attn: CEO

	 Email: akrieg@checkmatepharma.com

	
	 With a copy to:

		
	 Name:
	  	Charles Yon, Esq.
		  	[***]
	
	 If to Licensor, addressed to:

		
	 Name:
	  	Cytos Biotechnology AG
	 Street:
	  	Wagistrasse 25
	 City:
	  	8952 Schlieren
	 Country:
	  	Switzerland
	 Attn:
	  	CEO

			
	 With a copy to:

		
	 Name:
	  	VISCHER AG
	 Street:
	  	Aeschenvorstadt 4
	 City:
	  	4010 Basel
	 Country:
	  	Switzerland

 13.12    Waiver. A waiver by either Party of any of the terms and conditions
of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof. All rights, remedies, undertakings, obligations and agreements contained in this
Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party. 

13.13    Severability. When possible, each provision of this Agreement shall be interpreted in such manner
as to be effective and valid under Law, but if any provision of this Agreement is held to be prohibited by or invalid under Law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the
remainder of this Agreement. The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision. 

13.14    No Implied License. No right or license is granted to Licensor hereunder by implication, estoppel,
or otherwise to any know-how, patent or other Intellectual Property right owned or controlled by Checkmate or its Affiliates. 

13.15    Interpretation. The words “include,” “includes” and “including’’
shall be deemed to be followed by the phrase ‘‘without limitation,” All references herein to Articles, Sections, and Schedules shall be deemed references to Articles and Sections of, and Schedules to, this Agreement unless the context
shall otherwise require. Unless the context otherwise requires, countries shall include territories. 

13.16    Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an
original, and all of which together shall he deemed to be one and the same instrument. A facsimile or a portable document format (PDF) copy of this Agreement, including the signature pages, shall be deemed an original. 

[SIGNATURE PAGE FOLLOWS] 

 IN WITNESS WHEREOF, the Parties have caused
this Agreement to be executed and delivered by their respective duly authorized officers as of the Signing Date. 
  

			
	 CYTOS BIOTECHNOLOGY LTD
	  	 CHECKMATE PHARMACEUTICALS, LLC.

		
	 By: /s/ Christian Itin
	  	 By: /s/ Arthur M. Krieg

		
	 Name: Christian Itin
	  	 Name: Arthur M. Krieg

		
	 Title: CEO
	  	 Title: CEO

 SCHEDULE 1.18 

CYT003 DESCRIPTION 
 [***]

 SCHEDULE 1.42 

LICENSOR PATENTS 
 [Schedule begins on
following page.] 

					
	Cytos Biotechnology AG	  	CONFIDENTIAL	  	29.09.2014

  

			
	Patent Family:	  	Packaging of ISS into Virus-Like Particles: Method of Preparation and Use
		
	Applicant:	  	Cytos Biotechnology AG
		
	Investors:	  	Martin Bachmann, Tazio Stormi, Patrick Maurer, Alain Tissot, Katrin Schwarz, Edwin Meijerink, Gard Lipowaky, Paul Pumpens, Indulis Clelens, Regina Renhofa

  

																											
	Cytos
Reference
No.	 	 Country 	 	Application Type	 	Application 
Date	 	Application
No.	 	Priority
Country	 	Earliest      
Priority
Date	 	Earliest      
Priority
No.	 	Additional    
Priorities	 	Publication
Date	 	Publication
No.	 	Grant
Date            	 	Patent
No.	 	Status
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010ATLP
	 	AT	 	 Validated after
EPC
	 	16.09.2002	 	E-0147957	 	US	 	14.09.2001	 	60/310,991	 	60/374,145 (22.04.2002)	 	27.03.2003	 	1450856	 	11.11.2009	 	E447907	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010AD00
	 	AD	 	 PCT Based with
Priority
	 	16.09.2002	 	2002333224	 	US	 	14 09.2001	 	60/310,934	 	60/374,145 (22.04.2002)	 	 	 	 	 	22.01.2009	 	2002339224	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010AD01
	 	AD	 	 Divisional
	 	16.09.2002	 	2009200115	 	US	 	14 09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	05.02.2009	 	2009200115	 	10.08.2012	 	2009200115	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010DEEP
	 	BE	 	 Validated after
EPC
	 	16.09.2002	 	2777600.4	 	US	 	14.09.2001	 	60/310.994	 	60/374,145 (22.04.2002)	 	27.03.2003	 	1450856	 	11.11.2009	 	1460856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010CA00
	 	CA	 	
PCT Based with Priority
	 	16.09.2002	 	2,492,826	 	US	 	14.09.2001	 	60/318/934	 	60/374,145 (22.04.2002)	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010CHEP
	 	CH	 	 Validated after
EPC
	 	16.09.2002	 	2777600.4	 	US	 	14.09.2001	 	60/318/994	 	60/374,145 (22.04.2002)	 	27.03.2003	 	1460856	 	11.11.2009	 	1450856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010CN00
	 	CN	 	 PCT Based with
Priority
	 	16.09.2002	 	2817935.8	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	27.03.2005	 	1599623A	 	11.05.2011	 	ZL02817935.8	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010CYEP
	 	CY	 	 Validated after
EPC
	 	16.09.2002	 	20101100114	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	27.03.2003	 	1450956	 	11.11.2009	 	1450856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010DEEP
	 	DE	 	 Validated after
EPC
	 	16.09.2002	 	60234375.5-08	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	27.03.2003	 	1450856	 	11.11.2009	 	1450856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010DKEP
	 	DK	 	 Validated after
EPC
	 	16.09.2002	 	2777600.4	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	27.03.2003	 	1450856	 	11.11.2009	 	1450856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010EP00
	 	EP	 	 PCT Based with
Priority
	 	16.09.2002	 	2777600.4	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	27.03.2003	 	1450856	 	11.11.2009	 	1450856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010EP01
	 	EP	 	 Divisional
	 	16.09.2002	 	9014047.6	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	16.06.2010	 	2196217	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010ESEP
	 	ES	 	 Validated after
EPC
	 	16.09.2002	 	2777600.4	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	27.03.2003	 	1450856	 	11.11.2009	 	1450856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010FREP
	 	FR	 	 Validated after
EPC
	 	16.09.2002	 	2777600.4	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	27.03.2003	 	1450856	 	11.11.2009	 	1450856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010GBEP
	 	GB	 	 Validated after
EPC
	 	16.09.2002	 	2777600.4	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	27.03.2003	 	1450856	 	11.11 2009	 	1450856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010GREP
	 	GR	 	 Validated after
EPC
	 	16.09.2002	 	2777600.4	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	27.03.2003	 	1450856	 	11.11.2009	 	10670598	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010HK00
	 	HK	 	 Based on European Patent
Application
	 	16.09.2002	 	4110189.6	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	01.04.2005	 	1067856	 	26.03.2010	 	10670598	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010IEEP
	 	IE	 	 Validated after
EPC
	 	16.09.2002	 	2777600.4	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	27.03.2003	 	1460856	 	11.11.2009	 	1450856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010:N00
	 	IN	 	 PCT based with
Priority
	 	16.09.2002	 	551/CHENP/2004	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	 	 	 	 	26.11.2009	 	236919	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010:N01
	 	IN	 	 Divisional
	 	16.09.2002	 	3160/CHENP/2009	 	US	 	14.09.2001	 	60/318,994	 	60/374,145 (22.04.2002)	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010ITEP
	 	IT	 	 Validated after
EPC
	 	16.09.2002	 	27776004	 	US	 	14.09.2001	 	60/310,994	 	06/374,145 (22.04.2002)	 	27.03.2003	 	1450856	 	11.11.2009	 	1450856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010JP00
	 	JP	 	 PCT Based with
Priority
	 	16.09.2002	 	2003-528575	 	US	 	14.09.2001	 	60/318,994	 	06/374,145 (22.04.2002)	 	16.06.2005	 	2005.517632	 	21.05.2010	 	4516748	 	
Granted

  
 1/2 

					
	Cytos Biotechnology AG	  	CONFIDENTIAL	  	29.09.2014

  

																											
	Cytos
Reference
No.	 	 Country 	 	Application
Type	 	Application 
Date	 	Application
No.	 	Priority
Country	 	Earliest      
Priority
Date	 	Earliest      
Priority
No.	 	Additional    
Priorities	 	Publication
Date	 	Publication
No.	 	Grant
Date            	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P101JP01
	 	JP	 	 Divisional
	 	16.09.2002	 	2009-091943	 	US	 	14.09.2001	 	60/318,994	 	06/374,145 (22.04.2002)	 	17.08.2011	 	4749475	 	27.05.2011	 	4749475	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010NLEP
	 	NL	 	 Validated after
EPC
	 	16.09.2002	 	2777600.4	 	US	 	14.09.2001	 	60/318,994	 	06/374,145 (22.04.2002)	 	27.03.2003	 	1450858	 	11.11.2009	 	1450856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010PC00
	 	PC	 	 With Priority
	 	16.09.2002	 	PCT/IB02/04132	 	US	 	14.09.2001	 	60/318,994	 	06/374,145 (22.04.2002)	 	27.03.2003	 	WO2003/024481A2	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010SEEP
	 	SE	 	 Validated after
EPC
	 	16.09.2002	 	2777600.4	 	US	 	14.09.2001	 	60/318,994	 	06/374,145 (22.04.2002)	 	27.03.2003	 	1450856	 	11.11.2009	 	1450850	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010TREP
	 	TR	 	 Validated after
EPC
	 	16.09.2002	 	2777600.4	 	US	 	14.09.2001	 	60/318,994	 	06/374,145 (22.04.2002)	 	27.03.2003	 	1450856	 	11.11.2009	 	1450856	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010US00
	 	US	 	 Provisional
	 	14.09.2001	 	60/310,994	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010US01
	 	US	 	 Provisional
	 	22.04.2002	 	60/374,145	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010US02
	 	US	 	 With Priority
	 	16.09.2002	 	10/244,065	 	US	 	14.09.2001	 	60/318,994	 	06/374,145 (22.04.2002)	 	29.05.2003	 	2003/0099668A1	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010US03
	 	US	 	
Contribution/Additional
	 	10.11.2011	 	13/294,0008	 	US	 	14.09.2001	 	60/318,994	 	06/374,145 (22.04.2002)	 	29.11.2012	 	2012/0301499A1	 	08.04.2014	 	8,691,209	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1010US04
	 	US	 	
Contribution/Additional
	 	23.01.2014	 	14/162,600	 	US	 	14.09.2001	 	60/318,994	 	06/374,145 (22.04.2002)	 	 	 	 	 	 	 	 	 	
Pending

  
 2/2 

					
	Cytos Biotechnology AG	  	CONFIDENTIAL	  	29.09.2014

  

			
	Patent Family:	  	Packaging of Innumostimulatory substances into Virus-Like Particles: Method of Preparation and Use
		
	Applicant:	  	Cytos Biotechnology AG
		
	Investors:	  	Martin Bachmann, Andreas Cornelius, Vania Manolova, Patrick Maurer, Edwin Meijerink, Kari G. Proba, Katrin Schwarz

  

																											
	Cytos
Reference
No.	 	 Country 	 	Application
Type	 	Application 
Date	 	Application
No.	 	Priority
Country	 	Earliest      
Priority
Date	 	Earliest      
Priority
No.	 	Additional    
Priorities	 	Publication
Date	 	Publication
No.	 	Grant
Date            	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1038AY00
	 	AU	 	 PCT Based with
Priority
	 	25.03.2004	 	2004224762	 	US	 	26.03.2003	 	60/457,348	 	 	 	24.12.2009	 	2004224762	 	08.04.2010	 	2004224782	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1038CHEP
	 	CH	 	 Validated after
EPC
	 	25.03.2004	 	04723207.9	 	US	 	26.03.2003	 	60/457,348	 	 	 	07.10.2004	 	1605973	 	26.09.2012	 	1605873	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1038DEEP
	 	DE	 	 Validated after
EPC
	 	25.03.2004	 	602004039458.0	 	US	 	26.03.2003	 	60/457,348	 	 	 	07.10.2004	 	1605973	 	26.09.2012	 	1605873	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1038EP00
	 	EP	 	 PCT Based with
Priority
	 	25.03.2004	 	04723207.9	 	US	 	26.03.2003	 	60/457,348	 	 	 	07.10.2004	 	1605973	 	26.09.2012	 	1605873	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1038FREP
	 	FR	 	 Validated after
EPC
	 	25.03.2004	 	04723207.9	 	US	 	26.03.2003	 	60/457,348	 	 	 	07.10.2004	 	1605973	 	26.09.2012	 	1605873	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1038GBEP
	 	GB	 	 Validated after
EPC
	 	25.03.2004	 	04723207.9	 	US	 	26.03.2003	 	60/457,348	 	 	 	07.10.2004	 	1605973	 	26.09.2012	 	1605873	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1038IN00
	 	IN	 	 PCT Based with
Priority
	 	25.03.2004	 	2391/CHEN/2005	 	US	 	26.03.2003	 	60/457,348	 	 	 	 	 	 	 	19.05.2009	 	234298	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1038PC00
	 	PC	 	 With Priority
	 	25.03.2004	 	PCT/EP04/003165	 	US	 	26.03.2003	 	60/457,348	 	 	 	07.10.2004	 	WO2004/094940A1	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1038US00
	 	US	 	 PCT Based with
Priority
	 	25.03.2004	 	10/550,519	 	US	 	26.03.2003	 	60/457,348	 	 	 	09.11.2006	 	2006/0251677A1	 	14.04.2009	 	7,517,520	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1038US01
	 	US	 	
Continuation/Additional
	 	25.03.2009	 	12/410,085	 	US	 	26.03.2003	 	60/457,348	 	 	 	22.04.2010	 	2010/0098722A1	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1038ZA00
	 	ZA	 	 PCT Based with
Priority
	 	25.03.2004	 	2005/07063	 	US	 	26.03.2003	 	60/457,348	 	 	 	 	 	 	 	28.03.2007	 	2005/07063	 	
Granted

  
 1/1 

					
	Cytos Biotechnology AG	  	CONFIDENTIAL	  	29.09.2014

  

			
	Patent Family:	  	Scalable Fermentation Process
		
	Applicant:	  	Cytos Biotechnology AG
		
	Investors:	  	Frank Hennecke, Martin Rhiel, Marcel Emmerling, Holger Pfrunder, Philipp Steiner

  

																											
	Cytos
Reference
No.	 	 Country 	 	Application
Type	 	Application 
Date	 	Application
No.	 	Priority
Country	 	Earliest      
Priority
Date	 	Earliest      
Priority
No.	 	Additional     
Priorities	 	Publication
Date	 	Publication
No.	 	Grant
Date            	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049AU00
	 	AU	 	 PCT Based with
Priority
	 	24.05.2006	 	2006251098	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	30.11.2006	 	2006251098	 	05.01.2012	 	2006251098	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049CA00
	 	CA	 	 PCT Based with
Priority
	 	24.05.2006	 	2608579	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049CHEP
	 	CH	 	 Validated after
EPC
	 	24.05.2006	 	6777243.4	 	EP	 	26.05.2005	 	5011416.4	 	 	 	30.11.2006	 	1885847	 	 	 	1885847	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049CN00
	 	CN	 	 PCT Based with
Priority
	 	24.05.2006	 	2.0068E+11	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	02.07.2008	 	CN101213294A	 	27.03.2013	 	ZL200680023620.0	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049DEEP
	 	DE	 	 Validated after
EPC
	 	24.05.2006	 	6777243.4	 	EP	 	26.05.2005	 	5011416.4	 	 	 	30.11.2006	 	1885847	 	 	 	1885847	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049EP00
	 	EP	 	 Priority Founding
	 	26.05.2005	 	5011416.4	 	 	 	 	 	 	 	 	 	29.11.2006	 	1725642	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049EP01
	 	EP	 	 Priority Founding
	 	21.07.2005	 	5106729.6	 	 	 	 	 	 	 	 	 	24.01.2007	 	1746165	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049EP02
	 	EP	 	 PCT Based with
Priority
	 	24.05.2006	 	6777243.4	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	30.11.2006	 	1885847	 	 	 	1885847	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049ESEP
	 	ES	 	 Validated after
EPC
	 	24.05.2006	 	6777243.4	 	EP	 	26.05.2005	 	5011416.4	 	 	 	30.11.2006	 	1885847	 	 	 	1885847	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049GREP
	 	FR	 	 Validated after
EPC
	 	24.05.2006	 	6777243.4	 	EP	 	26.05.2005	 	5011416.4	 	 	 	30.11.2006	 	1885847	 	 	 	1885847	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049GBEP
	 	GB	 	 Validated after
EPC
	 	24.05.2006	 	6777243.4	 	EP	 	26.05.2005	 	5011416.4	 	 	 	30.11.2006	 	1885847	 	 	 	1885847	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049IEEP
	 	IE	 	 Validated after
EPC
	 	24.05.2006	 	6777243.4	 	EP	 	26.05.2005	 	5011416.4	 	 	 	30.11.2006	 	1885847	 	 	 	1885847	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049IL00
	 	IL	 	 PCT Based with
Priority
	 	24.05.2006	 	187341	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	 	 	 	 	01.12.2012	 	187341	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049IN00
	 	IN	 	 PCT Based with
Priority
	 	24.05.2006	 	9176/DELNP/2007	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049ITEP
	 	IT	 	 Validated after
EPC
	 	24.05.2006	 	6777243.4	 	EP	 	26.05.2005	 	5011416.4	 	 	 	30.11.2006	 	1885847	 	 	 	1885847	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049JP00
	 	JP	 	 PCT Based with
Priority
	 	24.05.2006	 	2008-512847	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	18.12.2006	 	2006-545401	 	27.12.2013	 	5442251	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049NLEP
	 	NL	 	 Validated after
EPC
	 	24.05.2006	 	6777243.4	 	EP	 	26.05.2005	 	5011416.4	 	 	 	30.11.2006	 	1885847	 	 	 	1885847	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049NZ00
	 	NZ	 	 PCT Based with
Priority
	 	24.05.2006	 	563708	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	27.08.2010	 	563709	 	07.12.2010	 	563708	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049PC00
	 	PC	 	 With Priority
	 	24.05.2006	 	PCT/EP2006/062628	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	30.11.2006	 	WO2006/125821A2	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049SG00
	 	SG	 	 PCT Based with
Priority
	 	24.05.2006	 	200718035-9	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	 	 	 	 	15.07.2010	 	137907	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049US00
	 	US	 	 PCT Based with
Priority
	 	24.05.2006	 	11/321,023	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	13.01.2011	 	2011/0008831A1	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049US01
	 	US	 	
Continuation/Additional
	 	22.12.2011	 	13/335,008	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	20.12.2012	 	2012/0322103A1	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1049US02
	 	US	 	
Continuation/Additional
	 	07.04.2014	 	14/247,097	 	EP	 	26.05.2005	 	5011416.4	 	 EP05106729.6

(21.07.205)
	 	 	 	 	 	 	 	 	 	
Pending

  
 1/1 

					
	Cytos Biotechnology AG	  	CONFIDENTIAL	  	29.09.2014

  

			
	Patent Family:	  	Scalable Process for Protein Purification
		
	Applicant:	  	Cytos Biotechnology AG
		
	Inventors:	  	Susanne Richter, Simon Topeil

  

																											
	Cytos
Reference
No.	 	 Country 	 	Application
Type	 	Application 
Date	 	Application
No.	 	Priority
Country	 	Earliest      
Priority
Date	 	Earliest      
Priority
No.	 	Additional     
Priorities	 	Publication
Date	 	Publication
No.	 	Grant
Date            	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1050CHEP
	 	CH	 	 Validated after
EPC
	 	20.06.2006	 	6792464.7	 	EP	 	21.06.2005	 	5105513.5	 	 	 	28.12.2006	 	1893751	 	05.03.2013	 	1893751	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1050DEEP
	 	DE	 	 Validated after
EPC
	 	20.06.2006	 	6792464.7	 	EP	 	21.06.2005	 	5105513.5	 	 	 	28.12.2006	 	1893751	 	07.03.2013	 	1893751	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1050EP00
	 	EP	 	 Priority Founding
	 	20.06.2006	 	5105513.5	 	 	 	 	 	 	 	 	 	27.12.2006	 	1736638	 	08.03.2013	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1050EP01
	 	EP	 	 PCT Based with
Priority
	 	20.06.2006	 	6792464.7	 	EP	 	21.06.2005	 	5105513.5	 	 	 	28.12.2006	 	1893751	 	09.03.2013	 	1893751	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1050FREP
	 	FR	 	 Validated after
EPC
	 	20.06.2006	 	6792464.7	 	EP	 	21.06.2005	 	5105513.5	 	 	 	28.12.2006	 	1893751	 	10.03.2013	 	1893751	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1050GBEP
	 	GB	 	 Validated after
EPC
	 	20.06.2006	 	6792464.7	 	EP	 	21.06.2005	 	5105513.5	 	 	 	28.12.2006	 	1893751	 	11.03.2013	 	1893751	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1050PC00
	 	PC	 	 With Priority
	 	20.06.2006	 	PCT/EP2006/063373	 	EP	 	21.06.2005	 	5105513.5	 	 	 	28.12.2006	 	WO2006/136566A1	 	12.03.2013	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1050US00
	 	US	 	 PCT Based with
Priority
	 	20.06.2006	 	11/922,591	 	EP	 	21.06.2005	 	5105513.5	 	 	 	19.02.2009	 	2009/0048433A1	 	13.03.2013	 	7,888,888	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1050US01
	 	US	 	
Continuation/Additional
	 	23.12.2010	 	12/978,033	 	EP	 	21.06.2005	 	5105513.5	 	 	 	 	 	 	 	14.03.2013	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1050US02
	 	US	 	
Continuation/Additional
	 	22.08.2011	 	13.214,825	 	EP	 	21.06.2005	 	5105513.5	 	 	 	23.08.2012	 	2012/0214976A1	 	15.03.2013	 	 	 	
Closed

  
 1/1 

					
	Cytos Biotechnology AG	  	CONFIDENTIAL	  	29.09.2014

  

			
	Patent Family:	  	Processes for Packaging Oligonucleotides into Virus-Like Particles of RNA Bacteriophages
		
	Applicant:	  	Cytos Biotechnology AG
		
	Inventors:	  	Matthias Kinzler, Karl Proba

  

																											
	Cytos
Reference
No.	 	 Country 	 	Application
Type	 	Application 
Date	 	Application
No.	 	Priority
Country	 	Earliest      
Priority
Date	 	Earliest      
Priority
No.	 	Additional     
Priorities	 	Publication
Date	 	Publication
No.	 	Grant
Date            	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070ATEP
	 	AT	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	31.07.2013	 	2032592	 	31.07.2013	 	E624690	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070AU00
	 	AU	 	 PCT Based with
Priority
	 	12.06.2007	 	2007260236	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	23.06.2013	 	2007260236	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070AU01
	 	AU	 	 Divisional
	 	12.06.2007	 	2013204383	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070BEEP
	 	BE	 	 Validated after
EPC
	 	12.06.2007	 	7764627.10	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592.0	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070UGEP
	 	UG	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070BR00
	 	BR	 	 PCT Based with
Priority
	 	12.06.2007	 	P10718651.0	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070CA00
	 	CA	 	 PCT Based with
Priority
	 	12.06.2007	 	2655108	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070CHEP
	 	CH	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070CN00
	 	CN	 	 PCT Based with
Priority
	 	12.06.2007	 	1.0078E+11	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	24.06.2009	 	CN101466720A	 	02.01.2013	 	200780021918.20	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070CYEP
	 	CY	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070CZEP
	 	CZ	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070DEEP
	 	DE	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	602007032006.20	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070DKEP
	 	DK	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070EEEP
	 	EE	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	E000556	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070EP00
	 	EP	 	 PCT Based with
Priority
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070EP01
	 	EP	 	 Divisional
	 	12.06.2007	 	12167784.2	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	05.12.2012	 	2032592	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070ESEP
	 	ES	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070FIEP
	 	FI	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070FREP
	 	FR	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

  
 1/1 

					
	Cytos Biotechnology AG	  	CONFIDENTIAL	  	29.09.2014

  

																											
	Cytos
Reference
No.	 	 Country 	 	Application
Type	 	Application 
Date	 	Application
No.	 	Priority
Country	 	Earliest      
Priority
Date	 	Earliest      
Priority
No.	 	Additional     
Priorities	 	Publication
Date	 	Publication
No.	 	Grant
Date            	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070GBLP
	 	GB	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070GREP
	 	GR	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	3081500	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070HUEP
	 	HU	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	E07784627	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070IEEP
	 	IE	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070IL00
	 	IL	 	 PCT Based with
Priority
	 	12.06.2007	 	193520	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070IN00
	 	IN	 	 PCT Based with
Priority
	 	12.06.2007	 	1019/DELNP/2008	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070ISEP
	 	IS	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070ITEP
	 	IT	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070JP00
	 	JP	 	 PCT Based with
Priority
	 	12.06.2007	 	2009-514696	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	19.11.2009	 	2009-539907	 	20.12.2013	 	5437797	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070JP01
	 	JP	 	 Divisional
	 	12.06.2007	 	2013-255691	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070KR00
	 	KR	 	 PCT Based with
Priority
	 	12.06.2007	 	10-2009-7000353	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070LTEP
	 	LT	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070LULP
	 	LU	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070LVEP
	 	LV	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070MCEP
	 	MC	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070MTEP
	 	MT	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070MX00
	 	MX	 	 PCT Based with
Priority
	 	12.06.2007	 	MX/02008/015529	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	29.05.2012	 	299594	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070NLEP
	 	NL	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070NZ00
	 	NZ	 	 PCT Based with
Priority
	 	12.06.2007	 	573622	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	22.12.2011	 	573622	 	02.04.2012	 	573622	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070PC00
	 	PC	 	 With Priority
	 	12.06.2007	 	PCT/EP2007/005189	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	WO2007/144150A1	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070PLEP
	 	PL	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070PTEP
	 	PT	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070ROEP
	 	RO	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070RU00
	 	RU	 	 PCT Based with
Priority
	 	12.06.2007	 	2008131507	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	03.09.2012	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070SEEP
	 	SE	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

  
 1/1 

					
	Cytos Biotechnology AG	  	CONFIDENTIAL	  	29.09.2014

  

																											
	Cytos
Reference
No.	 	 Country 	 	Application
Type	 	Application 
Date	 	Application
No.	 	Priority
Country	 	Earliest      
Priority
Date	 	Earliest      
Priority
No.	 	Additional     
Priorities	 	Publication
Date	 	Publication
No.	 	Grant
Date            	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070SG00
	 	SG	 	 PCT Based with
Priority
	 	12.06.2007	 	20000097-3	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070SG01
	 	SG	 	 Divisional
	 	12.06.2007	 	201104247-0	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	20.07.2011	 	172696	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070SIEP
	 	SI	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070SKEP
	 	SK	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	E14870	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070TREP
	 	TR	 	 Validated after
EPC
	 	12.06.2007	 	7764627.1	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	21.12.2007	 	2032592	 	31.07.2013	 	2032592	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070US00
	 	US	 	 PCT Based with
Priority
	 	12.06.2007	 	12/304.620	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	28.10.2010	 	2010/0273237A1	 	24.09.2013	 	8.541.559	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070US01
	 	US	 	
Continuaton/Additional
	 	18.07.2013	 	13/942.483	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070US02
	 	US	 	 Divisional
	 	18.07.2013	 	13/945.697	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070US03
	 	US	 	 Divisional
	 	18.07.2013	 	13/945.708	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1070ZA00
	 	ZA	 	 PCT Based with
Priority
	 	12.06.2007	 	2008/10109	 	US	 	12.06.2006	 	60/812.592	 	PCT/2006/069734 (14.12.2006)	 	 	 	 	 	24.02.2010	 	2008/10109	 	
Granted

  
 1/1 

					
	Cytos Biotechnology AG	  	CONFIDENTIAL	  	29.09.2014

  

			
	Patent Family:	  	Oligonucleotides containing high concentrations of guanine monomers
		
	Applicant:	  	Cytos Biotechnology AG
		
	Inventors:	  	Brian Sproat

  

																											
	Cytos
Reference
No.	 	 Country 	 	Application
Type	 	Application 
Date	 	Application
No.	 	Priority
Country	 	Earliest      
Priority
Date	 	Earliest      
Priority
No.	 	Additional     
Priorities	 	Publication
Date	 	Publication
No.	 	Grant
Date            	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1084AU00
	 	AU	 	 PCT Based with
Priority
	 	12.12.2007	 	2007333147	 	US	 	12.06.2006	 	60/869.588	 	 	 	 	 	 	 	03.04.2014	 	2007133147	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1084AU01
	 	AU	 	 Divisional
	 	12.12.2007	 	2013704442	 	US	 	12.06.2006	 	60/869.588	 	 	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1084CA00
	 	CA	 	 PCT Based with
Priority
	 	12.12.2007	 	2671873	 	US	 	12.06.2006	 	60/869.588	 	2007333147	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1084CN00
	 	CN	 	 PCT Based with
Priority
	 	12.12.2007	 	200780049850.9	 	US	 	12.06.2006	 	60/869.588	 	2007133147	 	23.12.2009	 	CN101611048A	 	07.11.2012	 	ZL200780049850.9	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1084EP00
	 	EP	 	 PCT Based with
Priority
	 	12.12.2007	 	7060549.5	 	US	 	12.06.2006	 	60/869.588	 	 	 	19.06.2008	 	2125054	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1084IN00
	 	IN	 	 PCT Based with
Priority
	 	12.12.2007	 	3334/CHENP/2009	 	US	 	12.06.2006	 	60/869.588	 	 	 	 	 	 	 	 	 	 	 	
Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1084JP00
	 	JP	 	 PCT Based with
Priority
	 	12.12.2007	 	2009-541546	 	US	 	12.06.2006	 	60/869.588	 	 	 	22.04.2010	 	2010-512169	 	10.10.2013	 	5389662	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1084PC00
	 	PC	 	 With Priority
	 	12.12.2007	 	PCT/US2007/087183	 	US	 	12.06.2006	 	60/869.588	 	 	 	19.06.2008	 	WO2008/073960A2	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1084US00
	 	US	 	 Provisional
	 	12.12.2006	 	60/869.668	 	US	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Closed

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1084US01
	 	US	 	 With Priority
	 	12.12.2007	 	11/954.511	 	US	 	12.06.2006	 	60/869.588	 	 	 	12.06.2008	 	2008/0139797A1	 	19.11.2013	 	8586728	 	
Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
P1084US02
	 	US	 	
Continuation/Additional
	 	15.10.2013	 	14/054.068	 	US	 	12.06.2006	 	60/869.588	 	 	 	 	 	 	 	 	 	 	 	
Pending

  
 1/1 

 SCHEDULE 1.63 

TECHNOLOGY AND PROGRAM TRANSFER PLAN 
  

	1	 PROJECT STAKEHOLDERS AND CONTRACTUAL
STATUS 

  

					
	Party	  	Role/Tasks in the Project	  	Contact/Actions
	 [***]
	  	 Production of oligonucleotide G10

 
 [***]
  

Stability study of oligonucleotide G10.
  

Storage of G10
	  	 [***]

 
 Storage of materials secured and pre-paid by
Cytos until December 31, 2015.
  
 Extension of Storage agreement beyond that
period required.

	 [***]
	  	 CYT003-QbG10 DS production.

 
 [***]
	  	 [***]

 
 Storage of materials secured and pre-paid by
Cytos until December 31, 2015.
  
 Extension of storage agreement beyond that
period required.

	 [***]
	  	 Analytics of oligonucleotide G10

 
 [***]
  

Storage of materials for analytical testing.
  

Storage of stability samples (except G10)
	  	 [***]

 
 Storage of materials secured and pre-paid by
Cytos until December 31, 2015.
  
 Extension of storage agreement beyond that
period required.

	 [***]
	  	 Development of in-vivo and in-vitro potency tests.
  

Storage of materials for potency testing.
	  	 [***]

 
 Storage of materials secured and pre-paid by
Cytos until December 31,2015.
  
 Extension of storage agreement beyond that period
required.

  
 SCHEDULE 1.63 

	2	 TECHNOLOGY TRANSFER ACTIVITIES 

 

					
	Task	  	Timeline	  	Responsible
	Cytos to transfer Documentation to Checkmate	  	Within 5 Business Days of Closing	  	Cytos
	 Cytos to relieve third party project stakeholders from their confidentiality obligations
owed to Cytos vis-a-vis Checkmate
  

•   [***]
	  	Within 5 Business Days of Closing	  	Cytos
	Cytos to connect third party project stakeholders with point of contact at Checkmate and facilitate Checkmate entering into agreements with such project stakeholders	  	Within 5 Business Days of Closing	  	Cytos/Checkmate
	 Cytos to assign ownership of Licensor Materials stored at third party project stakeholders
to Checkmate
  

•   [***]
	  	Upon payment for such Licensor Materials by Checkmate	  	Cytos
	 Checkmate to set up new stability study in order to maintain GMP status of materials

 
 •   Oligonucleotide G10
(material stored at Avecia and Fujifilm, stability performed at Avecia)
	  	At Checkmate’s discretion following Closing	  	Checkmate

  

	3	 TRANSFERED MATERIALS 

 

											
	Material/Equipment	  	Purpose of Use	  	Amounts Transfered	  	Storage Place	  	Docs	  	Comment
	MCB Q08.20030325	  	Qbeta MCB	  	82 vials	  	FCS	  	 DR-030228-CYT-01
 BR-030327-WA1-01
 QAR-050314-GH2-01
 COA-030718-RJ1-01
 BC-030721-RJ1-01
 SPC-030423-NS1-02
 JOS-131023-FDB1-01

AP-131022-FDB1-01

B3134-MCB-001

Certificate of Analysis
 B3134-MCB-001
 Compliance Statement

B3134 MCB Study Protocol
	  	Vials stored at FCS to be sent to FDB

  
 SCHEDULE 1.63 

											
	Material/Equipment	  	Purpose of Use	  	Amounts Transfered	  	Storage Place	  	Docs	  	Comment
	WCB Q08.20050519	  	Qbeta WCB	  	50 vials	  	FCS	  	 BR-050527-WA1-01
 PR-050601-HF1-01
 QAR-050606-GH2-01
 BC-051101-NS1-01
 CER-080124-HT4-01
 SPC-050613-GHZ-01
 JOS-131023-FOB1-01

AP-131022-FDB1-01

B3134-WCB-001

Certificate of Analysis B3134-WCB-001

Compliance Statement B3134 WCB Study Protocol
	  	Vials stored at FCS to be sent to FDB
	Oligonucleotide G10	  	GMP-Grade	  	Available on request 26 g (CHF 75 000)	  	Avecia	  	 MBR-140328-AVE1-01

COA-140328-AVE1-01

COC-140328-AVE1-01

CER-140328-AVE1-01
	  	 
	CYT003-QbG10(API)	  	Non-clinical use	  	 Available on request (CHF 30/mg)

Est Run 2 (3.57 mg/ml)
 4 x 30 ml

2 x 250 ml
 1 x 80.6 ml
	  	FDB	  	TR-140226-FDB1-01
COA-140220-FDB1-01 COA-140220-FDB1-02 COA-140220-FDB1-03	  	 
	QbG10 standard ([***] material NBA0674-17-21)	  	Standard for in-vivo and in-vitro potency
development	  	 20 vials

1 x 30 ml
	  	BSL	  	OA-140220-FDB1-01	  	 
	Qb [***] Batch 11	  	Potency test (in-vivo)	  	50 x 0.2 ml (3.1 mg/ml	  	BSL	  	 TR-070715-LON-01
 COA-140225-KA2-02
	  	 
	 Standard IS055

(Qb dimer standard
	  	Standard for Qb dimer testing	  	150 x 0.4 ml	  	Solvias	  	COA-140113-KA2-01
	  	 
	 Standard IS027

(G10 ± x nucleotides)
	  	Standard for QBG10 testing	  	20 x 250 μl	  	Cytos	  	 COA-131014-KA2-01
 COA-100407-WG1-01
	  	 
	 Standard IS040

(QbG10 standard)
	  	Standard for QBG10 testing	  	100 x 0.1 ml	  	Solvias	  	COA-140127-KA2-01
	  	 

  
 SCHEDULE 1.63 

											
	Material/Equipment	  	Purpose of Use	  	Amounts Transfered	  	Storage Place	  	Docs	  	Comment
	E. coli lysate pMt0105 
(not released as HCP standard IS020)	  	Used for goat immunization against HCP, Standard for host cell protein testing	  	3 x 50 ml	  	Cytos	  	 LR-050308-RS2-01
 TR-061205-RS2-01
	  	 
	Goat anti pMt0105 antiserum	  	Antiserum for HCP ELISA	  	 10 x 5 ml

2 x 50 ml
	  	Cytos	  	 TR-050722-NWL-01
 LR-060307-CA1-01
 TR-060829-CA1-01
	  	 
	Goat anti pMt0105 raw sera	  	Goat raw sera for purification of antiserum used in HCP ELISA	  	4 bottles	  	Cytos	  	TR-050722-NWL-01
	  	 
	Antibody 3H10	  	Mouse anti-QB lgG2a for in vivo potency test	  	 10 x 0.01 ml (0.66 mg/ml) 5 x 0.1 ml
(0.66 mg/ml)
 2 x 1 ml (0.66 mg/ml)
 2 x 0.01 ml (0.518 mg/ml)
2 x 0.1 ml (0.518 mg/ml)
 2 x 1 ml (0.518 mg/ml)
	  	BSL	  	TR-131216-MCR1-01	  	 
	Anti-Qb scFv-Fc fusion protein	  	For in-vivo potency test	  	 3 x 0.1 ml (2.688 mg/ml)

1 x 1 ml (2.688 mg/ml)
 10 x 0.1 ml {1.22 mg/ml) 1 x 1 ml (1.22
mg/ml)
	  	BSL	  	TR-140414-MCR1-01	  	 
	 Anti-Qb5 (hlgG1)

(monoclonal human antibody against Qbeta)
	  	For in-vitro efficacy experiments and establishment of in vitro potency assay	  	Available on request (CHF 110/mg)	  	Cytos	  	 	  	 
	PMDC05 cells	  	Cell line for establishment of in-vitro potency test	  	(see comment)	  	BSL	  	 Narita M., et al. (2009) Leukemia
Research 33,
 1224-1232;
 Yamahira A. et al.
(2012) Leukemia Research 36,
 1541-1546
	  	Cell line was licensed from Niigata University. Transfer of the cell line would need to be approved by Niigata
University and an annual license fee would need to be paid

  
 SCHEDULE 1.63 

 4 CMC DOCUMENTS TO BE TRANSFERRED
TO CHECKMATE 
 4.1 Documents need to be transferred for the CYT003-QbG10 Process 

 

					
	Product / Module	  	Development reports	  	Production Reports
	 Oligonucleotide G10

 
 —   Intermediate

 
 —   Chemical
synthesis
	  	 TR-090518-LON1-01

TR-051007-SA1-01

TR-051130-KM1-01

TR-060504-KM1-01

TR-060720-RNA-01

TR-070130-RNA-01

TR-070226-RNA-01

TR-070404-RNA-01

TR-070504-RNA-01

TR-080404-KM1-01

TR-080410-LON-01

TR-080410-LON-02

TR-080710-BSP-01

TR-130626-AVE1-01

TR-130816-AVE1-01

TR-140121-AVE1-01

TR-140129-AVE1-01
	  	 Batch Biospring
18:
 BR-071211-BSP1-01

RM R-070803-WB1-01

BC-080520-BSP1-01

COA-080814-BSP1-01

SPC-070816-WG1-01

 
 Avecia GMP batch AZJ 100000:

MBR-140205-AVE1-01

MBR-140317-AVE1-01

MBR-140327-AVE1-01

MBR-140328-AVE1-01

MBR-140328-AVE1-02

MBR-140328-AVE1-03

BRR-140414-AVE1-01

	 Cell banks
  

—   MCB Qbeta
  

—   WCB Qbeta
	  	 MCB Q08.20030325:

DR-030228-CYT-01
	  	 MCB
Q08.20030325:

BR-030327-WA1-01

QAR-050314-GH2-01

COA-030718-RJ 1-01

BC-030721-RJ 1-01

SPC-030423-NS1-02

 
 WCB Q08.20050519:

BR-050527-WA1-01

PR-050601-HF1-01

QAR-050606-GH2-01

BC-051101-NS1-01

CER-080124-HT 4-01

SPC-050613-GH2-01

  
 SCHEDULE 1.63 

					
	Product / Module	  	Development reports	  	Production Reports
	 	  	 	  	 Fujifilm
documents:
 JOS-131023-FDB1-01

AP-131022-FDB1-01

B3134-MCB-001 Certificate of Analysis

B3134-MCB-001 Compliance Statement

B3134-WCB-001 Certificate of Analysis

B3134-WCB-001 Compliance Statement

B3134 MCB Study Protocol
 83134 WCB Study Protocol

	 Qbeta Dimer

 
 —   Intermediate for
CYT003 – QbG10(API)
  

—   Biotechnihological process
	  	 Fermentation:

DR-040719-RM1-01

TR-050531-RM1-01

TR-060127-PH1-01

TR-060822-LON-01

TR-061129-LON-01

TR-070322-PH1-01

TR-070327-PH1-01

TR-070515-LON-01

TR-080808-KR3-01

TR-140128-FDB1-01

 
 Fujifilm reports:

TR-140128-FDB1-01

 
 Downstream Processing:

TR-051110-RS2-01

TR-060612-TS1-01

TR-060822-LON-01

TR-060824-PK1-01

TR-061026-PK1-01

TR-061103-RS2-01

TR-061103-TS1-01

TR-061129-LON-01

TR-070312-GC2-01
	  	 Cytos
fermentation batch QBF110:
 BR-1004-01_QBF110

PR-060216-TS1-01

QAR-060516-Ml1-04

 
 Lonza Qbeta AIX-load batch B10:

COA-070323-LON-01

BC-070329-LON-01

BR-070201-LON-01

BR-070201-LON-02

BR-070203-LON-01

BR-070203-LON-02

BR-070203-LON-03

BR-070203-LON-04

BR-070203-LON-05

BR-070203-LON-06

BR-070204-LON-01

BR-070204-LON-02

BR-070204-LON-03

BR-070204-LON-04

BR-070204-LON-05

BR-070205-LON-01

BR-070205-LON-02

BR-070205-LON-03

BR-070205-LON-04

 

  
 SCHEDULE 1.63 

					
	Product / Module	  	Development reports	  	Production Reports
	 	  	 TR-070515-LON-01
 TR-070608-SR1-01
 TR-070706-PKl-01
 TR-071105-PKl-01
 TR-081217-BC2-01
 TR-081217-MS4-01
 TR-140226-FDB1-01
  
	  	 BR-070206-LON-01
 BR-070206-LON-02
 BR-070206-LON-03
 BR-070206-LON-04
 BR-070207-LON-01
 BR-070207-LON-02
 BR-070207-LON-03
 BR-070208-LON-01
 BR-070208-LON-02
 BR-070209-LON-01
 BR-070209-LON-02
 BR-070209-LON-03
 BR-070209-LON-04
 BR-070210-LON-01
 BR-070210-LON-02
 BR-070210-LON-03
 BR-070211-LON-01
 BR-070211-LON-02
 BR-070212-LON-05
 BR-070213-LON-03
 BR-070214-LON-04
 BR-070215-LON-01
 BR-070216-LON-03
 BR-070223-LON-03
 BR-070227-LON-03
 BR-070301-LON-01
 BR-070301-LON-02
 BR-070328-LON-01
  

Qbeta Dimer Batch QDP011:

PR-070529-TS1-01

QAR-070731-Ml1-01

QAR-081023-HT-01

QCR-081024-MA4-01

  
 SCHEDULE 1.63 

					
	Product / Module	  	Development reports	  	Production Reports
	 	  	 	  	 Qbeta Dimer Batch
QDP012:
 PR-071116-TS1-01

QAR-080414-Ml1-01

SPC-080423-HG1-01

 
 Qbeta Dimer Batch QDP013:

BRR-111012-OS3-02

COA-111103-KA1-03

SPEC-1-0003-02

	 CYT003-QbG10(API)

 
 —   Drug Substance

 
 —   Biotechnological
process
	  	 TR-051007-SA1-01
 TR-060228-PKl-01
 TR-060619-KM1-01
 TR-060911-KM1-01
 TR-070219-MJ 1-01
 TR-070313-PKl-01
 TR-070417-SA1-01
 TR-070523-SA1-01
 TR-070724-SA1-01
 TR-080220-SA1-01
 TR-080818-SA1-01
  

Fujifilm reports:
 TR-140226-FDB1-01

TR-140424-FDB1-01

COA-140220-FDB1-03

COA-140220-FDB1-01
	  	 Batch
QG10023:
 BR-3015-03/QG10023

BC-120210-HF1-02

BC-121003-WJ1-01

BRR-111020-SD2-02

COA-111104-KA1-03

ASF-CYT003-QbG10-06

SPEC-A-0022-03

	 CYT003-QbG10(IMP)

 
 -   Drug Product

 
  
	  	 Filter validation:

VP-091029-PAL1-01
 VP-090902-PAL1-01

VR-091214-PAL1-01
 VR-091028-PAL1-01
	  	 Batch BAG
131502:
 BR-130522-BAG1-01
 BR-130425-BAG1-02

BRR-130514-081-01
 COC-130529-BAG1-01

  
 SCHEDULE 1.63 

					
	Product / Module	  	
Development reports
	  	
Production Reports

	 —   Aseptic filling in
glass vials
	  	 	  	
COA-130610-BAG1-02

COA-140212-BAG1-02

SPEC-D-0025-01

SPEC-D-0028-02

 4.2    Documents to be transferred for the analytics of the oligonucleotide G10 

 

													
	Parameter	  	Method	  	Test instruction (Cytos reference)	  	Instructions / Examples test record	  	Development reports	  	Validation reports	  	Other
	 Oligonucleotide G10 purity and
impurities
	  	
IEX-HPLC
	  	
QTM – 000327 (optimized Avecia method)
	  	
ATI-140218-AVE-01

	  	
TR-130717-AVE1-01

TR-140129-AVE1-01
	  	 	  	 
	 Oligonucleotide G10 content
	  	
Spectrophotometry
	  	
QTM – 000342 (Avecia reference)
	  	
ATI-140317-AVE-01

	  	
TR-130718-AVE1-01

TR-140306-AVE1-01
	  	 	  	 
	 Content and identity of oligonucleotide
impurities
	  	
UV/LC-MS
	  	
QTM – 000357 (Avecia reference)
	  	
ATI-140317-AVE-01

	  	
TR-140227-AVE1-01
	  	 	  	 

 4.3    Documents to be transferred for analytics of Qbeta Dimer and CYT003-QbG10 

 

													
	Parameter	  	Method	  	Test instruction (Cytos reference)	  	Instructions / Examples test record	  	Development reports	  	Validation reports	  	Other
	 Visible Particles and Colour
	  	
Visual Inspection
	  	
Generic Method / OI-0192 /

EP 2.9.20
	  	
OI-0192-04

OI-0192
	  	 	  	
MVR-060712-SD2-01

	  	 
	 Turbidity
	  	
Turbidimetry
	  	
Generic method /

OI-0174

EP 2.2.1
	  	
OI-0174-05

OI-0174-05
	  	
TR-060317-SB1-01

	  	
MVR-OI-017 4-04
	  	 

  
 SCHEDULE 1.63 

													
	Parameter	  	Method	  	Test instruction (Cytos reference)	  	Instructions / Examples test record	  	Development reports	  	Validation reports	  	Other
	 pH
	  	
Potentionmetric determination
	  	
Generic method /

OI-0151

EP 2.2.3
	  	
OI-0054-06

OI-0054-06
	  	 	  	
MVR-OI-0054-02

	  	 
	 Conductivity
	  	
Conductivity
	  	
Generic method /

OI-0151

EP 2.2.38
	  	
OI-0151-04

OI-0151-04
	  	 	  	
MVR-OI-0151-02

	  	 
	 Sterility
	  	
Sterility
	  	
Generic method /

EP 2.6.1
	  	 	  	 	  	
VR-120702-CON1-01
	  	 
	 Identity
	  	
Peptide mapping / RP-HPLC
	  	
OI-0204
	  	
OI-0204-01 (incl. SINs)

OI-0204-01-09

	  	
TR-060217-BJ2-01
 TR-080308-DB1-01
TR-080402-DB1-01
TR-080426-DB1-01
	  	
MVR-OI-0204-01

	  	
Transfer to Solvias
TVR-120706-SOL1-01

	 Protein content
	  	
Spectrophotometry
	  	
OI-0215
	  	
OI-0215-01

OI-0215-01-40

	  	
TR-071119-BE1-01

	  	 	  	 
	 Protein content
	  	
BCA assay
	  	
OI-0219
	  	
OI-0219-02 (incl. SINs)

OI-0219-02-13

	  	
TR-080623-SD2-01

	  	
MVR-OI-0219-01

	  	
Transfer to Solvias
TVR-120613-SOL1-01
 TVR-130904-SOL1-01

	 Oligonucleotide content
	  	
Spectrophotometry
	  	
OI-0213
	  	
OI-0213-01 (incl. SINs)

OI-0213-01-19

	  	
TR-071015-302-01

	  	
MVR-OI-0213-01

	  	
Transfer to Solvias
TVR-120625-SOL1-01

	 Thiol content
	  	
Ellman’s
	  	
OI-0218
	  	
OI-0218-04 (incl. SINs)

OI-0218-04-37

	  	
TR-070601-KA1-01

	  	
MVR-OI-0218-V01

	  	
Transfer to Solvias
TVR-120612-SOL1-01

	 Integrity / Purity
	  	
SE-HPLC / UV
	  	
OI-0214
	  	
OI-0204-02 (incl. SINs and Qbeta
Dimer-specific addendum)
 OI-0204-02-10
	  	
TR-070404-HS2-01

	  	 	  	
Transfer to Solvias
TVR-130731-SOL1-01

  
 SCHEDULE 1.63 

													
	Parameter	  	Method	  	Test instruction (Cytos reference)	  	Instructions / Examples test record	  	Development reports	  	Validation reports	  	Other
	 VLP integrity/purity
	  	
SE-HPLC/UV
	  	
OI-0202
	  	
OI-0204-02 (incl. SINs and
CYT003-QbG10-specific addendum)
 OI-0202-03-67
	  	
TR-100831-DB1-01

	  	
MVR-OI-0202-03
 MVR-OI-0202-V06
	  	
Transfer to Solvias
TVR-120727-SOL1-01

	 VLP integrity/purity
	  	
AF4 / UV-MALS
	  	
SOP-P0582
	  	
SOP-P0582-01 LR-100420-RC1-01
	  	
TR-071212-DB1-01

	  	 	  	
Transfer to Solvias
TVR-120716-SOL1-01

	 Oligonucleotide G10 integrity
	  	
IEX-HPLC
	  	
OI-0182 (Cytos method)
	  	
OI-0182-03 (incl. SINs)

OI-0182-03-02
 (incl. SINs)
	  	
TR-070430-HK1-01
 TR-070301-HK1-01
	  	
MVR-OI-0182-01
 MVR-OI-0182-02
MVR-OI-0182-03
	  	
Transfer to Solvias
TVR-120703-SOL1-01

	 Protein impurities and degradation
	  	
LDS-PAGE / silver staining
	  	
Generic method / OI-0209 / 
EP 2.2.31
	  	
OI-0209-05 (incl. SINs)

OI-0209-05-16

	  	
TR-060628-SD2-01

	  	
MVR-OI-0209-03
 MVR-OI-0209-04
MVR-OI-0209-V05
	  	
Transfer to Solvias
TVR-120807-SOL1-01

	
Non-reducible Qbeta dimer
	  	
LDS-PAGE / silver staining
	  	
Generic method / OI-0209 / 
EP 2.2.31
	  	
OI-0209-05 (incl. SINs)

OI-0209-05-16

	  	
TR-070920-BE1-01

	  	
MVR-OI-0209-04

	  	
(Characterization report TR-100621-DB1-01)

	 Modifications
	  	
IEF
	  	
OI-0234
	  	
OI-0234-02 (incl. SINs)

OI-0234-02-10

	  	
TR-090602-BE1-01

	  	 	  	
Transfer to Solvias
TVR-120717-SOL1-01

	 Protein purity / Modifications
	  	
CZE
	  	
N/A
	  	 	  	
Solvias S.52.DOK.S141_01
	  	 	  	
(Development at Solvias)

  
 SCHEDULE 1.63 

													
	Parameter	  	Method	  	Test instruction (Cytos reference)	  	Instructions / Examples test record	  	Development reports	  	Validation reports	  	Other
	 Potency
	  	
In vivo test

(mouse assay)
	  	
N/A
	  	
BSL SOP draft attached to method validation plan
MVP-140409-BIS1-01_invivoPotencyA

ssay_ELISA
	  	
TR-100706-O53-01,
 TR-100826-5B1-01

(Short Cytos summary in vivo Potency Assay)
	  	
MVP-140409-BIS1- 01_invivoPotencyAss ay_ELISA

MVP-140319-BIS1- 01_invivoPotencyAss ay_invivoPart

MVP-140222-BIS1- 01_invivoPotencyAss ay_ELISA

(no validation report, validation at BSL interrupted)
	  	
(Development at BSL)

	 Potency
	  	
In vitro test (cell assay)
	  	
N/A
	  	 	  	
(Short Cytos summary in vitro Potency Assay)
	  	 	  	
Cell line papers (Development at BSL)

	 Residual nucleic acid
	  	
RiboGreen assay (fluorometric)
	  	
SOP-P0616
	  	
SOP-P0616-01
	  	
TR-071014-SB1-01

	  	 	  	 
	 Host Cell DNA content
	  	
Threshold
	  	
OI-0133
	  	
OI-0133.05 (incl. SINs) 
OI-0133-05-23
	  	
TR-060915-581-01
 TR-070112-581-01
	  	
MVR-OI-0133-V02
 MVR-OI-0133-04
	  	 
	 E.coli Host Cell Protein content
	  	
Immunoassay
	  	
OI-0216
	  	
OI-0216-02 (incl. SINs) 
OI-0216-02-20
	  	
TR-060418-O53-01
 TR-080128-OS3-01
TR-100215-SB1-01
	  	
MVR-OI-0216-01

	  	 
	 Bacterial endotoxin content
	  	
LAL assay
	  	
Generic method / OI-0184 / 
EP 2.6.14 method D / 
Solvias SOP

C.52.S5262_01
	  	
OI-0184-05 (incl. SINs) 
OI-0184-05-11 
SOPs-120720-SOL1-01
	  	
TR-060324-SC1-01

	  	
MVR-OI-0184-V04
 VR-120626-SOL1-01 VR-120712-SOL1-01
	  	 
	 Bioburden (Total aerobic microbial cell counts
and Total
	  	
Microbial enumeration test
	  	
Generic method / EP 2.6.12
	  	
SOP-120622-SOL1-01
	  	 	  	 	  	 

 Other:
MVR-140214-KA2-01 (Yearly evaluation of validation status of analytical methods for CYT003-QbG10, Oligonucleotide G10 and Qbeta
transferred to Solvias AG) 

  
 SCHEDULE 1.63 

	4.4	 Documents to be transferred for product-specific in-house standards
used for analytics of Qbeta Dimer and CYT003-QbG10 

  

							
	Product	  	Standard Name	  	Specifications	  	CoA
	 	 	 	 
	Oligonucleotide G10 ± x nucleotides	  	IS027	  	SPC-IS027-02	  	COA-131014-KA2-01
	 	 	 	 
	CYT003-QbG10	  	IS040	  	SPEC-IS040-03	  	COA-140127-KA2-01
	 	 	 	 
	Qbeta	  	IS048	  	SPEC-IS048-02	  	COA-140225-KA2-02
	 	 	 	 
	Qbeta Dimer	  	IS055	  	SPEC-IS055-01	  	COA-140113-KA2-01

  
 SCHEDULE 1.63 

	5	 PRECLINICAL REPORTS TO BE
TRANSFERED TO CHECKMATE 

  

	5.1	 Preclinical reports on CYT003 

 

	5.1.1	 Non-GLP reports 

 

			
	Study title	  	Study type
	 	 
	PK report No 1 Half-life of Qb in mouse	  	PK
	 	 
	Pk report No 1 Pharmacokinetics of QbG10 in mouse	  	PK
	 	 
	CYT003-QbG10: PK report No 2 Serum half-life of QbG10 in Sprague-Dawley rats injected intravenously with QbG10	  	PK
	 	 
	CYT003-QbG10: PK report No 3 Pharmacokinetics of QbG10 in Sprague-Dawley rats after subcutaneous injection	  	PK
	 	 
	CYT003-QbG10: PK report No 4, Stability of QbG10 in human serum in vitro	  	PK
	 	 
	PPD report No 2 Stimulation of human T and B cells by G10	  	PD
	 	 
	PPD report No 3 TLR9-dependent signaling of G10	  	PD
	 	 
	PPD report No 4 Stimulation of mouse dendritic cells by QbG10 in vivo and in vitro	  	PD
	 	 
	PPD report No 5 Induction of T cell expansion and IFNy production by QbG10 in mice	  	PD
	 	 
	PPD report No 6 Efficacy of QbG10 in a ragweed-based allergy and asthma model in mice	  	PD
	 	 
	CYT003-QbG10: PPD report No 7 Uptake of QbGl0 by human pDCs in the presence of Qb-pecific
antibodies	  	PD
	 	 
	CYT003-QbG10: PPD report No 8 Stimulation of human PBMCs in the presence of
Qb-pecific antibodies	  	PD

  
 SCHEDULE 1.63 

			
	Study title	  	Study type
	 	 
	CYT003-QbG10: PPD report No 9 Upregulation of ICOS-L on human pDCs treated with QbGl0 in the presence
and absence of Qb-specific antibodies	  	PD
	 	 
	CYT003-QbG10: PPD report No 10 Analysis of IgG subclasses in Sprague-Dawley rats immunized with QbGl0 or QbpGlu	  	PD
	 	 
	Report of Antibody Determination from: Effects of QbGl0 Following Repeat-Dose Subcutaneous Administration to
the Lewis Rat (Covance Study 2970/001)	  	PD

  

	5.1.2	 GLP-reports (Toxicology Studies) 

 

					
	Study title	  	Study type	  	Study No
	 		 
	Acute Intravenous Toxicity Test in Rats following a Single Administration of QBG10	  	Single dose acute toxicity	  	506169
	 		 
	Repeat Dose and Local Tolerance Toxicity Study in Rats Following Multiple Subcutaneous Administrations of
QBG10	  	Repeat dose, local tolerance	  	505893
	 		 
	Local Tolerance and Toxicity Study of QbG10 in Rats with 7 Subcutaneous Injections	  	Repeat dose, local tolerance	  	512497
	 		 
	Effects of QbG10 Following Repeat-Dose Subcutaneous Administration to the Lewis Rat	  	Repeat dose, safety pharmacology	  	2970/001
	 		 
	8 Week Toxicity and Tolerance Study of AllQbG10 in Rats with 9 Subcutaneous Injections	  	Repeat dose, local tolerance	  	514714
	 		 
	QbGl0 Testing for Mutagenic Activity with Salmonella typhimurium TA 1535, TA 100, TA 1537 and TA 98 and
Escherichia coli WP2uvrA	  	AMES test (Testing mutagenic activity)	  	782861

  
 SCHEDULE 1.63 

	6	 CLINICAL REPORTS TO BE
TRANSFERRED TO CHECKMATE 

  

	6.1	 Completed Clinical Studies with CYT003: 

 

							
	Study Number	  	lnvestigational Product	  	Phase	  	Indication
	 	 		 
	CYT003-QbG10 02	  	CYT003	  	1	  	None
	 	 		 
	CYT003-QbG10 03	  	CYT003	  	2a	  	Atopic Dermatitis
	 	 		 
	CYT003-QbG10 08	  	CYT003	  	2a	  	Allergic Rhino-conjunctivitis (ARC)
	 	 		 
	CYT003-QbG10 09	  	CYT003	  	2b	  	ARC
	 	 		 
	CYT003-QbG10 11	  	CYT003	  	2a	  	Allergic Asthma
	 	 		 
	CYT003-QbG10 12	  	CYT003	  	2b	  	Allergic Asthma
	 	 		 
	CYT005-AllQbG10 01	  	CYT003 + Allergen extract	  	2a	  	Perennial ARC
	 	 		 
	CYT005-AllQbG10 02	  	CYT003 + Allergen extract	  	2a	  	Seasonal ARC
	 	 		 
	CYT005-AllQbG10 03	  	CYT003 + Allergen extract	  	2a	  	Perennial ARC
	 	 		 
	CYT005-AllQbG10 04	  	CYT003 + Allergen extract	  	2	  	Perennial ARC
	 	 		 
	CYT004-MelQbG10 01-03	  	MelQbG10	  	1/2a	  	Malignant Melanoma Stage II-IV
	 	 		 
	CYT004-MelQbG10 04	  	MelQbG10	  	2a	  	Stage III-IV

 Access to the following documents relating to the above list of clinical studies will be provided to Checkmate. Copies of all
electronic documents will be provided. Paper records achieved by Cytos may be accessed if needed at Checkmates expense. 
  

	 	•	 	 Protocols 

  
 SCHEDULE 1.63 

	 	•	 	 Protocol Amendments 

  

	 	•	 	 Case Report Forms 

  

	 	•	 	 Investigators Brochures 

 

	 	•	 	 Clinical Study Reports 

 

	 	•	 	 Statistical Analysis Plans 

 

	 	•	 	 Trial Master Files (archived as paper documents) 

 

	7	 DOCUMENTS RELATING TO REGULATORY
FILINGS 

  

	 	•	 	 IND CYT003 study 12 (BB-IND15217) 

 

	7.1	 Documents relating to CMC for study 12 

 

	 	•	 	 IMPD CYT003-QbG10 12 

  

	7.2	 Documents relating to CMC for study 13 

 

	 	•	 	 Draft IMPD CYT003-QbG10 13 

 

	7.2.1	 Scientific advice provided for CYT003 by competent authorities 

 

	 	•	 	 [***] 

  
 SCHEDULE 1.63EX-10.8

 Exhibit 10.8 

CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 AMENDMENT NO. I TO LICENSE AGREEMENT 

THIS AMENDMENT NO I (the Amendment) is made as of August 15, 2017 (the Amendment Effective Date) by and between KUROS BIOSCIENCES
AG (formerly Cytos Biotechnology, LTD), a company registered in Switzerland whose registered office is at Wagistrasse 25, 8952 Schlieren, Switzerland (“Licensor”), and CHECKMATE PHARMACEUTICALS, INC., having its
registered office at One Broadway, 14lh Floor, Cambridge, MA 02142, USA, (“Checkmate”). Licensor and Checkmate may be referred to herein as a “Party” or,
collectively, as “Parties”. 
 WHEREAS 
  

	(A)	 Licensor and Checkmate entered into a License Agreement dated June 17, 2015 (the Agreement).

  

	(B)	 Pursuant to Section 13.8 (titled “Entire Agreement of the Parties, Amendment”) of the Agreement,
the Agreement may be amended only by the written agreement of the Parties. 

  

	(C)	 Licensor and Checkmate desire to amend the Agreement to classify Qb VLP Cancer Vaccines in the Field as
Licensed Compounds Series 4 and to mutually agree on the financial terms of Licensed Compounds Series 4 in accordance with the provisions of this Amendment. 

  

	(D)	 Additional IP required to develop Qb VLP Cancer Vaccines shall be included in Schedule 1.42 and the full cost
for the prosecution of these patents shall be borne by Checkmate. 

 NOW, THEREFORE, in consideration of the mutual covenants and
agreements set forth herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Licensor and Checkmate agree as follows: 
  

	1.	 Qb VLP Cancer Vaccines definition 

It is hereby agreed that the below Clause 1.55a will be added to Article I of the Agreement. 

1.55a “Qb VLP Cancer Vaccine” means any Qb VLP, including CYT003, covalently conjugated or co-formulated
with any tumor antigen and delivered by subcutaneous, intramuscular, or intradermal injection or other route of vaccination, but specifically excluding intra-tumoral adminstration. 

 

	2.	 Modification of 1.36 Licensed Compounds 

 It is hereby agreed that in Clause I .36 the text 

“belonging to one of the three following series” will be replaced with “belonging to one of the four following series” 

And l.36(a) will change from “Series I: CYT003 (further described in Schedule 1.18)” to “Series I: CYT003 (further described in Schedule 1.18)
but excluding Licensed Compounds in Series 4 (as defined in 1.36(d)) 
 and, in 1.36(c) “(other than those in Series I and 2)” will be replaced by
“(other than those in Series 1, 2 and 4)”. 
 Also, the following Clause 1.36(d) will be added at the end of Clause 1.36 

“(d) Series 4: any Qb VLP Cancer Vaccine 
  

	3.	 Modification of 1.37 Licensed Compound Series 

It is hereby agreed that in Clause 1.37 the text 

“referred to individually in 1.36(a), (b) and (c)” 

will be replaced with 
 “referred to individually in
1.36(a), (b), (c) and (d)” 
  

	4.	 Addition of Development Milestones for Licensed Compounds Series 4: 

It is hereby agreed that the following table will be added to the end of Clause 5.2.1. 

 

			
	Development Milestones: Licensed Compound Series 4
(l.36(d))	  	Payment (all in USD)
	 	 
	
Dosing of the first patient in the first Phase I clinical trial
	  	[***]
	 	 
	
Dosing of the first patient in the first Phase 2 clinical trial
	  	[***]
	 	 
	
Dosing of the first patient in the first Phase 3 clinical trial
	  	[***]
	 	 
	
Upon the first New Drug Application filing with the FDA for regulatory approval in the United States
	  	[***]
	 	 
	
Upon the first MAA filing for regulatory approval in the European Union
	  	[***]
	 	 
	
Upon the first MAA filing for regulatory approval in the first of: China or Japan
	  	[***]
	 	 
	
Upon the first approval ofa New Drug Application in the United States
	  	[***]
	 	 
	
Upon the first approval of an MAA in the European Union
	  	[***]
	 	 
	
Upon the first approval of an MAA in the first of: China or Japan
	  	[***]

  

	5.	 Milestones for Additional Products in Licensed Compound Series 4. 

 It is hereby agreed that the current Clause 5.2.2 is replaced by 

“5.2.2 Each milestone payment in this Section 5.2 shall be payable only upon the first achievement of such milestone for the first Licensed Product
from the same Licensed Compound Series and no amounts shall be due for subsequent or repeated achievements of such milestone in with Licensed Products from such Licensed Compound Series, except for Licensed Products in Licensed Compound Series 4.
For Licensed Products in Licensed Compound Series 4 each milestone payment shall be as stated in Section 5.2.1 for the first Licensed Products in Licensed Compound Series 4, milestone payments shall be reduced by [***] for the second Licensed
Products in Licensed Compound Series 4, and shall be reduced by [***] for the third Licensed Products in Licensed Compound Series 4. For subsequent Licensed Products in Licensed Compound Series 4 no milestone payments shall be payable. For purposes
of clarity, each milestone payment in this Section 5.2 shall be payable only one time irrespective of the number of indications pursued for such Licensed Product in Licensed Compound Series 1, 2, and 3. For Licensed Products in Licensed
Compound Series 4 each milestone payment may be payable up to 3 times with milestone payments for the second and third Licensed Products being reduced as described in this Section 5.2.2.” 

 

	6.	 Modification of Clause 5.2.3 

It is hereby agreed to replace the current text of clause 5.2.3 with the following: 

5.2.3 Milestones payments will be made on the first achievement of each milestone listed in Section 5.2.1 for Licensed Products in Licensed Compound
Series I, 2 and 3. Milestone payments will be paid on the first, second and third achievement of each milestone listed in Section 5.2.1 for Licensed Products in Licensed Compound Series 4, with milestones for the second and third achievement of
said milestone being reduced as described in Section 5.2.2.” 
  

	7.	 Royalty Payments 

The Royalty Payments for Licensed Products in Licensed Compound Series 4 shall be the same as the royalty payments for Licensed Compound Series 2 set forth in
the Agreement in Section 5.3 with the exception that only the first three Licensed Products in Licensed Compound Series 4 reaching the market shall be eligible for Royalty payments. For clarity, no Royalties are due for the fourth and any
subsequent Qb VLP Cancer Vaccine Licensed Product reaching the market. Therefore, it is hereby agreed that in Section 5.3.1 the table will be replaced with the table below: 

 

									
	Net Sales in the Territory of all Licensed
Products in a calendar year	  	Licensed
Compound
Series 1	  	Licensed
Compound
Series 2	  	Licensed
Compound
Series 3	  	Licensed
Compound
Series 4
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	
[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	
[***]
	  	[***]	  	[***]	  	[***]	  	[***]

 It is also hereby agreed to add the following to the end of Section 5.3.1: 

“For Licensed Products in Licensed Compound Series 1, 2 and 3 royalties are payable on all Licensed Product Net Sales, however for Licensed Products in
Licensed Compound Series 4 royalties are payable only on Net Sales of the first three Licensed Products in Licensed Compound Series 4.” 

	8.	 Addition of patents to Schedule 1.42 

It is hereby agreed to add the patents listed in Schedule I of this Amendment to Schedule 1.42 of the Agreement. 

 

	9.	 Existing terms and conditions 

Except as otherwise expressly amended by this Amendment No. 1, the terms and conditions of the Agreement shall remain in full force and effect, and
neither Party waives any right under the Agreement herein. 
  

	10.	 Counterparts 

This Amendment may be executed in any number of counterparts, each such counterpart shall be deemed to be an original instrument. and all such counterparts
together shall constitute but one agreement. Any such counterpart may contain one or more signature pages. 
 Remainder of page left blank intentionally

 SIGNED by the Parties or their duly authorized officers on the dates set forth below, to be effective on the
date set forth above. 
  

									
	 KUROS BIOSCIENCES AG
	 		 	 CHECKMATE PHARMACEUTICALS, INC

			
	Date: August 15, 2017	 		 	Date: August 16, 2017
					
	By:	 	/s/ Philippe Saudan	 		 	By:	 	/s/ Arthur M. Krieg
	Name: Philippe Saudan	 		 	Name: Arthur M. Krieg
	Title: CDO	 		 	Title: CEO

  
 5 

 Schedule 1 

Remainder of page left blank intentionally 

					
	Kuros Biosciences AGG	  		  	14.08.2017

  

  

			
	Patent Family:	  	In Vivo Activation of Antigen Presenting Cella for Enhancement of Immune Respond Induced by VLPs
	Applicant:	  	Kuros Biosciences AG
	Inventors:	  	Martin F. Bachmann, Franziska Lechner, Tazlo Stornl

  

																											
	Kuros
Reference
No.	  	Country	  	Application
Type	  	Application
Date	  	Application
No.	  	Priority
Country	  	Earliest
Priority
Date	  	Earliest
Priority
No.	  	Additional
Priorities	  	Publication
Date	  	Publication
No.	  	Grant
Date	  	Patent
No.	  	Status
	 P1009EPOO
	  	
EP
	  	PCT Based with Priority	  	16.09.2002	  	2783338.3	  	US	  	14.09.2001	  	60/318,967	  	 	  	27.03.2003	  	1425040	  	 	  	 	  	Pending
	 P1009JPOO
	  	
JP
	  	PCT Based with Priority	  	16.09.2002	  	2003-528574	  	US	  	14.09.2001	  	60/318,967	  	 	  	17.03.2005	  	2005-507388	  	21.08.2009	  	4360906	  	Granted
	 P1009PCOO
	  	
PC
	  	With Priority	  	16.09.2002	  	PCT/1802/04252	  	US	  	14.09.2001	  	60/318,967	  	 	  	27.03.2003	  	W02003/024480A2	  	 	  	 	  	Closed
	 P1009US04
	  	
us
	  	Continuation	  	20.12.2012	  	14/567,945	  	US	  	14.09.2001	  	60/318,967	  	 	  	12.11.2015	  	US2015-0320855	  	 	  	 	  	Pending

					
	Kuros Biosciences AGG	  		  	14.08.2017

  

  

			
	Patent Family:	  	 Molecular Antigen Array

	Applicant:	  	Kuros Biosciences AG
	Inventors:	  	 Wolfgang Renner, Martin Bachmann, Alain Tissct, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Plossek

  

																											
	Kuros
Reference
No.	  	Country	  	Application
Type	  	Application
Date	  	Application
No.	  	Priority
Country	  	Earliest
Priority
Date	  	Earliest
Priority
No.	  	Additional
Priorities	  	Publication
Date	  	Publication
no.	  	Grant
Date	  	Patent
No.	  	Status
	P1011AU00	  	AU	  	PCT Based with Priority	  	21.01.2002	  	2002226263	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	 	  	 	  	28.06.2007	  	2002228263	  	Granted
	P1011AU01	  	AU	  	Divisional	  	21.01.2002	  	2007202761	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	 	  	 	  	06.05.2010	  	2007202761	  	Granted
	P1011BR00	  	BR	  	PCT Based with Priority	  	21.01.2002	  	P10206566-5	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	 	  	 	  	 	  	 	  	Pending
	P1011CA00	  	CA	  	PCT Based with Priority	  	21.01.2002	  	2,433,316	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	 	  	 	  	13.08.2013	  	2433316	  	Granted
	P1011CHEP	  	CH	  	Validated after EPC	  	21.01.2002	  	2710211	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	25.07.2002	  	1370290	  	01.06.2016	  	1370290	  	Granted
	P1011CN00	  	CN	  	PCT Based with Pnortty	  	21.01.2002	  	02803869.X	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	07.04.2004	  	1487840A	  	21.02.2007	  	ZL02803869.X	  	Granted
	P1011JP01	  	JP	  	Divisional	  	21.01.2002	  	2008-274671	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	18.06.2009	  	2009-132689	  	11.01.2013	  	5175160	  	Granted

					
	 Kuros Biosciences AGG
	  		  	 14.08.2017

  

																											
	Kuros
Reference
No.	  	Country	  	Application
Type	  	Application
Date	  	Application
No.	  	Priority
Country	  	Earliest
Priority
Date	  	Earliest
Priority
No.	  	Additional
Priorities	  	Publication
Date	  	Publication
no.	  	Grant
Date	  	Patent
No.	  	Status
	P1011JP03	  	JP	  	Divisional	  	21.01.2002	  	2015-094858	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	19.11.2015	  	2015-205881	  	 	  	 	  	Pendng
	P1011NLEP	  	NL	  	Validated after EPC	  	21.01.2002	  	2710211	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	25.07.2002	  	1370290	  	01.06.2016	  	1370290	  	Granted
	P1011PC00	  	PC	  	With Priority	  	21.01.2002	  	PCT/IB02/00166	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	25.07.2002	  	WO2002/056905A2	  	 	  	 	  	Closed
	P1011RU01	  	RU	  	PCT Based with Prionty	  	21.01.2002	  	2003125363	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	 	  	 	  	27.03.2007	  	2295973	  	Granted
	P1011RU01	  	RU	  	Divisional	  	21.01.2002	  	2206141850	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	 	  	 	  	10.01.2012	  	2438701	  	Granted
	P1011US04	  	US	  	With Priority	  	18.01.2002	  	10/050,902	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	18.09.2003	  	2003/0175290A1	  	04.09.2007	  	7,264,810	  	Granted
	P1011US09	  	US	  	Continuation	  	17.01.2017	  	151407920	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	 	  	 	  	 	  	 	  	Pend ng
	P1001DEEP	  	DE	  	Validated after EPC	  	21.01.2002	  	2710211	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	25.07.2002	  	1370290	  	01.06.2016	  	1370290	  	Granted

					
	 Kuros Biosciences AGG
	  		  	 14.08.2017

  

																											
	Kuros
Reference
No.	  	Country	  	Application
Type	  	Application
Date	  	Application
No.	  	Priority
Country	  	Earliest
Priority
Date	  	Earliest
Priority
No.	  	Additional
Priorities	  	Publication
Date	  	Publication
no.	  	Grant
Date	  	Patent
No.	  	Status
	P1011EP00	  	EP	  	PCT Based with Prionty	  	21.01.2002	  	2710211	  	US	  	19.01,2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	25.07.2002	  	1370290	  	01.06.2016	  	1370290	  	Granted
	P1011EP01	  	EP	  	Divisional	  	21.01.2002	  	10012605.1	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	14.09.2011	  	2364727	  	 	  	 	  	Pending
	P1011FREP	  	FR	  	Validated after EPC	  	21.01.2002	  	2710211	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	25.07.2002	  	1370290	  	01.06.2016	  	1370290	  	Granted
	P1011GBEP	  	GB	  	Validated attar EPC	  	21.01.2002	  	2710211	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	26.07.2002	  	1370200	  	01.06.2016	  	1370290	  	Granted
	P1010IEEP	  	IE	  	Validated attar EPC	  	21.01.2002	  	2710211	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	25.07.2002	  	1370290	  	01.06.2016	  	1370290	  	Granted
	P1011IN00	  	IN	  	PCT Based with Priority	  	21.01.2002	  	1120/CHENP/2003	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	 	  	 	  	07.01.2009	  	227435	  	Granted
	P1011IN01	  	IN	  	Divisional	  	21.01.2002	  	1503/CHENP/2008	  	US	  	19.01.2001	  	60/262.379	  	 60/288.549

(04.05.2001);
 60/326.998

(05.10.2001);
 60/331.045

(07.11.2001);
	  	 	  	 	  	18.03.2011	  	246862	  	Granted

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]